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ABSTRACT 
The percentage of individuals older than 65 years of age is increasing. In 2008, approximately 
506 million individuals worldwide were older than 65. This number is expected to double and 
reach 14% of the world’s population by year 2040. With this increase, a higher number of older 
men and women are expected to experience deterioration in their bones and muscles leading to 
osteoporosis and sarcopenia respectively. Therefore, understanding the burden that osteoporosis 
and sarcopenia represent in older men and women could have major public health implications. 
 We studied the importance of areal and volumetric bone mineral density (vBMD) in 
fracture risk prediction in older men.  We found that low areal BMD (aBMD) and (vBMD) were 
both associated with multiple sites of fracture. Nonetheless, low vBMD was not found to be a 
better predictor of major osteoporotic fractures (Hip, spine wrist, shoulder) compared to aBMD, 
except at the spine. Subsequently, in the same cohort of older men, we found that low 
appendicular lean mass was positively associated with central and peripheral bone skeletal size, 
density and strength parameters that have been previously related to fractures. On the other hand, 
grip strength was only associated with site specific radial strength and geometric parameters. 
There was no association between leg power and the skeletal size, density and strength of older 
men after adjusting for appendicular lean mass and grip strength. These findings highlight the 
more important role of the mechanical load of the muscles on bones, compared to the muscle 
strength and power. Finally, we were interested in examining whether sarcopenia with or without 
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osteoporosis is associated with an increased risk of non-spine fractures. In this third paper, we 
demonstrated that men with both sarcopenia and low BMD are at a much higher risk for non-
spine fractures compared to men with either one or neither condition. On the other hand, low 
BMD with or without sarcopenia in older women was associated with an increased risk of 
fractures, suggesting that low BMD is the driving force of non-spine fractures in older women.  
Future research should investigate further the crosstalk between muscle and bones. There 
are currently multiple sarcopenia definitions. Therefore, a consensus on the definition for 
sarcopenia should be reached, so that diagnostic and therapeutic tools can be developed. 
Furthermore, dual-energy X-ray absorptiometry (DXA) remains the gold standard diagnostic tool 
for fracture risk assessment. 
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1.0  INTRODUCTION – THE MUSCULOSKELETAL SYSTEM 
The percentage of individuals older than 65 years of age is increasing. Back in 2008, 
approximately 506 million individuals worldwide were older than 65. This number is expected to 
double and reach 14% of the world’s population by year 2040 [1]. With this increase in the older 
population, a higher number of older men and women are expected to experience deterioration in 
their bone and muscle leading to osteoporosis and sarcopenia respectively. A similar decreasing 
trend in bone strength (density and quality), lean mass, and muscle strength is observed with age 
[2]. Based on these findings, it is believed that muscles and bones share genetic, biological, and 
physiological processes that may be triggering this well synchronized decline in both tissues. 
This review will provide some insight about the muscle bone interaction and etiologies in an 
attempt to better understand the factors that mediate this cross talk. This is an emerging field of 
research and many attempts are being made to understand the etiologies shared by both tissues so 
that preventive measures and interventions could be targeted to both simultaneously. 
Furthermore, musculoskeletal disorders are a major cause of disabilities worldwide and represent 
a major economical burden. The cost spent on musculoskeletal disorders is greater than the cost 
of breast cancer, stroke, and cardiovascular diseases combined [3]. Therefore, it is of primary 
importance to understand the burden that osteoporosis and sarcopenia represent on older men 
and women. 
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The purpose of this dissertation will be to study the epidemiology of osteoporosis and 
sarcopenia. Specifically, the combined effects of sarcopenia and osteoporosis on health outcomes 
such as fractures and falls will be studied. 
1.1 OSTEOPOROSIS 
1.1.1 Definition 
Osteoporosis is a condition defined as low bone mass and microarchitectural deterioration of 
bone tissue with a consequent increase in bone fragility and susceptibility to fracture [4].  The 
World Health Organization (WHO) defines osteoporosis based on bone mineral density (BMD) 
alone, and previous fracture [5]. This definition does not take bone quality and bone 
microarchitecture into consideration, and therefore doesn’t cover the full spectrum of bone 
strength. On the other hand, the National Institutes of Health (NIH) defines it as a skeletal 
disorder characterized by compromised bone strength predisposing a person to an increased risk 
of fracture [6].  The term bone strength includes both bone density and bone quality. Bone 
density is a reflection of bone mass and is expressed by grams per area or per volume depending 
on the measurement tool used. Bone quality is a reflection of the architecture, damage 
accumulation, turnover, and mineralization of the bones [7].  
The strength of bone is determined by both its material composition and geometric 
structure [7]. Bone geometry plays a major role in bone strength and hence, fracture risk [8]. As 
men and women age, the cross-sectional area of the medullary cavity increases, resulting in the 
reduction of the cortical area of bones. Furthermore, older individuals experience a thinning of 
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the bone cortex (poor geometry) because endocortical resorption exceeds periosteal apposition 
[9]. Another important geometric parameter is the distribution of cortical mass about the bone 
center.  It has been shown that resistance of bones to compressive loads and to bending depend 
on the cortical area and the distribution of cortical mass about the center respectively [10]. These 
are important geometric parameters to consider while assessing bone strength. 
Bone size, cortical thickness and porosity, trabecular number and thickness, and mineral 
content are all important factors in assessing bone strength [9]. A disruption in one or more of 
these factors could result in a decrease in bone strength and consequently, osteoporosis.  
1.1.2 Pathophysiology 
Normal and healthy bone is known to constantly remodel by osteoblast and osteoclast activity. 
The osteocytes, which represent 95% of all bone cells, are embedded in the matrix of bones and 
control the activity of osteoblasts and osteoclast located at the bone surface [11]. Continuous 
bone resorption followed by bone formation is necessary to maintain bone volume and calcium 
homeostasis [12]. During increased osteoclastic activity, the osteoblast formation also increases 
which indicates that these two processes may be coupled. The receptor activator of nuclear 
factor-kB ligand (RANKL), a tumor necrosis factor derived from osteocytes, was discovered and 
helped in clarifying how osteoblasts regulate osteoclast activity [13] [14] [15] [16]. Osteoclasts, 
under normal regulation, do not pathologically resorb bones.  As a matter of fact, the osteoblast-
derived factor RANKL is essential for osteoclast formation [17]. Osteoprotegerin (OPG), a 
decoy receptor, has the function of inhibiting the resorption by decreasing the differentiation and 
function of osteoclast. OPG prevents the osteoclast formation, attachment to bone, activation, 
and survival of osteoclasts. OPG inhibits the binding of RANKL to the receptor activator of 
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nuclear factor-kB (RANK) [18] [19] (Figure 1). RANK is a receptor located on the membrane of 
osteoclasts and osteoclasts precursors. Previous animal studies have shown that OPG deficient 
mice had increased osteoclast activity resulting in severe osteoporosis. In these mice, both 
trabecular and cortical porosity increased and parietal bone became thinner [20] [21]. The ratio 
of RANKL to OPG was shown to be an important determinant of bone resorption, with high 
RANKL and low OPG promoting bone resorption. As long as the RANKL to osteoprotegerin 
ratio is within the normal range, bone resorption remains under control [22]. The RANKL and 
OPG do not affect only BMD but also the geometry and strength of the bones [23] [24]. Changes 
in hormonal levels (estrogen, testosterone, etc.) and steroid intake were found to disrupt this 
balance by increasing the RANKL/osteoprotegerin ratio and consequently favoring osteoporosis 
and fractures. 
1.1.3 Radiographic diagnostic tools 
Based on the WHO approach, Dual-energy X-ray absorptiometry (DXA) is the gold standard 
diagnostic tool used to identify patients with osteoporosis [25] [26]. DXA was first introduced in 
the late 1980s early 1990s [27]. It’s low cost, quickness, low radiation and precision made it 
popular and commonly used by researchers and clinicians. DXA relies on two dimensional scans 
to provide areal bone mineral density (aBMD) measurements. To diagnose osteoporosis, the 
aBMD of the femoral neck is used to calculate the T-score. T score is obtained by subtracting the 
mean aBMD of the young normal population from the measured femoral aBMD and dividing by  
the standard deviation of the normal population: T-score= (Measured BMDa – Young adult 
mean BMDa)/ Young adult population SD.  
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Subjects are considered to have normal BMD if their T-score is greater than or equal to -
1. A T-score strictly below -1 is an indication of low bone mass: osteopenia is present if the T-
score is between -1 and -2.5, and osteoporosis if T-score is below or equal to -2.5. Using the 
WHO approach, T-score is calculated using mean femoral neck aBMD obtained from the 
National Health and Nutrition Examination Survey III reference data [28]. Young Caucasian 
women are used as the reference population in both men and women as recommended by the 
International Society for Clinical Densitometry (ISCD) [29]. However there are some 
controversies regarding the usage of young Caucasian women as the reference group. Other 
working groups propose to use gender-specific and ethnic specific reference data [30] [31]. 
Osteoporosis, diagnosed based on bone density alone, seems to miss a large proportion of 
individuals with low bone strength. As a matter of fact, most fractures occur in non-osteoporotic 
individuals [32] . Only 20% of osteoporotic individuals, diagnosed only based on femoral BMD, 
experience fractures. This may be due to the fact that the population of osteopenic subjects is 
much larger and that bone quality is not being captured for proper bone strength assessment. 
DXA has several limitations. Some trials have shown that the increase in aBMD does not 
explain the reduction in fracture risk [33] [34]. This may be because aBMD takes a long time to 
change despite earlier changes in bone turnover markers detected in the blood [35] [36]. Another 
limitation is that it relies on bone size to measure the aBMD which usually results in 
overestimation of BMD in subjects with large bones and underestimation in subjects with small 
bones [37] [38]. This contributes to some of the race/ethnic differences observed in aBMD. 
Moreover, DXA does not differentiate non-bone hyperdensities such as aortic calcifications and 
foreign bodies from actual bone which could result in overestimation of aBMD especially at the 
lumbar spine [39]. Also, DXA assumes that the soft tissue at the site of interest is homogenous. 
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However, soft tissues are a mixture of fat and muscle which don’t have the same composition 
[40]. A final limitation is that monitoring aBMD changes to assess therapy efficacy is 
controversial. Despite these limitations DXA is still the gold standard imaging technique used to 
diagnose osteoporosis. One of the reasons is because BMD linearly correlates and accounts for 
60-70% of bone strength  [41] [42] [39].    
As previously stated, DXA is currently the most widely used method to assess bone mass 
and diagnose osteoporosis. However, bones are three dimensional structures and using two 
dimensional scans to assess their density is limited. Additionally, DXA is an integrated measure 
of bone density without differentiating between the trabecular and cortical compartments. This 2 
dimensional imaging technique does not capture the size, shape, and geometry of bones. 
Advances in technology are making it possible to assess bone quality (microarchitecture and 
geometry) and obtain volumetric measurements of trabecular and cortical compartments. 
Although not commonly used in clinical settings because of high cost and lack of diagnostic 
cutoff points, these novel imaging techniques are improving the bone research field and could be 
a linchpin for future therapeutic breakthroughs. Many imaging techniques, such as Magnetic 
resonance imaging and quantitative ultrasonography, are currently being explored. However, this 
review will focus on the Quantitative Computed Tomography (QCT).   
QCT was first introduced in the late 1970s [39]. It was initially used for diagnostic 
purposes other than bones. The Quantitative Computed Tomography (QCT) is a more intuitive 
method of measuring bone density using a 3 dimensional approach. QCT is a 3 dimensional 
imaging technique that provides volumetric BMD (vBMD) instead of aBMD in which case size 
becomes irrelevant [43]. Furthermore, QCT can distinctively measure trabecular and cortical 
bones allowing a separate assessment of these bone compartments. This is an important 
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advantage since trabecular and cortical compartments have different metabolic activities [44]. 
Furthermore, QCT provides 3 dimensional geometric parameters and information about 
trabecular structure in central (Hip and Spine) and peripheral regions (radius and tibia) of the 
skeleton. It was designed to assess the BMD, bone size, shape of bones, as well as biomechanical 
measures. The parameters provide information about the resistance of bone to bending (cross 
sectional moment of inertia-CSMI), the bending strength (polar strength index-SSIp, axial 
strength index- SSIx), the torsional strength (section modulus-SM), and the ability of the bone to 
resist torsion (polar moment of inertia-PMI) [45]. The bone’s polar moments of inertia provide 
information about the ability of bones to resist torsion, whereas the axial moments measures the 
distribution of cortical bone mass about the center of the cross-section of the tubular bone [46]. 
The polar or axial strength strains are a reflection of the torsional and bending rigidity of the long 
bone shaft [47]. The section modulus is a reflection of the resistance of the bones to stress. If 
high, it means that a higher load is needed to cause mechanical failure [48]. 
At the hip, QCT helps in differentiating between cervical and trochanteric fractures. It 
also provides more information about femoral geometry and hip structure which were found to 
be associated with hip fractures independently of BMD [49] [50] [51]. Other parameters such as 
the cross-sectional area and medullary volume could be obtained as well to better assess quality 
of bones [52].  Cross sectional area, neck axis length and cortical thickness have been associated 
with bone failure load [53] [50]. 
In the lumbar spine area, QCT provides information about the trabecular compartment of 
the vertebrae. For accurate reading of these scans, at least two vertebrae should be seen by the 
radiologist. This is done mostly to reduce the radiation exposure [39]. Since trabecular and 
cortical compartments have different patterns of deterioration, assessing the vertebrae with QCT 
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provides more compartment-specific information compared to DXA. Geometric parameters are 
also important for bone quality assessment in the spine. The endplate area, cross-sectional area, 
or vertebral surface area have been shown to improve the correlation of BMD with failure load 
[54] [55] [56]. On the other hand, cortical thickness is difficult to measure in spine because of 
spatial resolution [57]. 
Peripheral QCT measures BMD, bone size, and shape of the radius and tibia. At the distal 
sites, the cortical and trabecular bone mineral content (BMC), cross-sectional area, and BMD can 
be measured. However, on the shaft of the bones the trabecular component does not exist but 
cortical thickness, endosteal, and periosteal circumference can be measured [58]. 
In pQCT, the section modulus, moment of inertia, and the SSI were correlated with 
failure load [59] [60] [61].  Despite the fact that pQCT provides more information about bone 
quality and strength, it was not found to better predict failure load compared to DXA alone [62]. 
QCT also has its limitations. The radiation received by the patient is much higher 
compared to DXA and this might be of concern since the gonads are in the scan field for central 
QCT [38]. Also, the high cost of the equipment makes it less readily available, especially for the 
central QCT. In addition, QCT is less precise and highly variable. There are currently no clear 
cut-off points used in QCT imaging to diagnose osteoporosis. Future endeavors to find a 
standard population that could be used for diagnostic purposes could make the QCT the gold 
standard imaging tool of choice.  
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1.1.4 Epidemiology 
Prevalence and incidence 
Currently, about 54 million Americans above age 50 have osteoporosis and low bone 
mass (10.2 million have osteoporosis and 43.4 million have low bone mass). This number is 
expected to increase and with it the number of osteoporotic fractures. The National Osteoporosis 
Foundation (NOF) expects it to increase to 64.4 million in 2020, and 71.2 million in 2030 [63]. It 
is estimated that the lifetime risk of any fracture is 40% and 13% in US women and men 
respectively [64]. With this increase in prevalence of osteoporosis, a higher number of fractures 
are expected, leading to an increase in morbidity and mortality [65]. Back in 2005, 
approximately 2 million incident fractures occurred. This number is now on the rise since a 
larger number of the US population has low bone mass. Although many are not detected, 
vertebral fractures represents 27% of fractures. Wrist fractures accounts for 19% of fractures, hip 
fractures 14%, and pelvic fractures 7% [65].  
There are gender and race differences in osteoporosis and fracture prevalence. Peak BMD 
and rate of BMD loss explain some of these disparities. Men have a higher peak BMD compared 
to women. As men and women age the average rate of hip BMD loss increases. Nonetheless, 
women tend to lose more bone than men especially after menopause [66]. In men, although the 
rate of BMD loss is moderate, those with low BMD at baseline experiences higher bone loss 
compared to men with normal BMD at baseline [67].  
Race differences also exist [68]. In both genders, peak BMD is the highest in African 
Americans [69] [70] [71]. 
The BMD of Mexican American women is higher than the BMD of Caucasians, but 
lower than BMD of African Americans. Asian women tend to have the lowest BMD [72] [73]. 
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These differences in older women could be attributed to the peak bone mass as well as the rate of 
bone loss. Indeed, white women lose twice more BMD than African American women.  These 
differences in BMD result in different risks of fractures among ethnic groups [6].  
As expected, African Americans experience the lowest rate of fractures. However, white 
women experience the higher risk of hip fractures compared to Asian women despite the fact that 
Asian women have a lower BMD [66] [74]. This may be due to poorer bone geometry and/or 
increase in fall frequency among Caucasian women.  
The hip, vertebral, and distal radius regions are the sites with the highest percentage of 
trabecular bone and this why they are the most common sites of insufficiency fractures 
 
Hip fracture 
Hip fractures represent less than 20 percent of osteoporotic fractures worldwide with the 
large majority seeking medical attention [75]. Therefore, hip fractures are easy to track and are 
used to determine osteoporosis burden. Another reason why hip fractures are important to assess 
is because they are associated with poor outcomes such as deep vein thrombosis, urinary tract 
infections, nosocomial infections, disability, and eventually death. Hip fracture was found to be 
associated with more disability and mortality than all other fractures combined [76]. 
Furthermore, they account for most fracture related expenditures [77]. About 20% of patients 
who experience a hip fracture die within a year [78]. The risk of hip fracture has been shown to 
increase exponentially with age with the great majority occurring above age 70. It occurs mostly 
in older women since they live longer, with women to men ratio of approximately 2 [79]. Most 
hip fractures result from a fall [80]. Nonetheless, it is important to note that there is a high 
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variability in hip fracture incidence across the world with higher magnitudes in women 
compared to men [81].  
In North America, hip fractures have been found to decrease between 1995 and 2005 in 
both men and women [82] [83]. In the US, white men and women continued to experience a 
decrease in incidence of hip fractures after 2005. Blacks and Asians didn’t experience any 
changes while a small non-significant increase in hip fracture rate was seen in Hispanic women 
[84].   
Northern Europe countries such as Iceland, Ireland, and Norway were found to have the 
highest risk of hip fractures. Countries around or below the equator were associated with a lower 
risk of hip fractures [85]. Globally, hip fractures follow more or less a similar trend in developed 
countries: increases in rates until the mid-1990s with a subsequent decrease after that. However, 
this is not the trend in Asian countries [81]. Cauley et al. hypothesized that this observed 
decrease could be due to one or more of these factors: release of bisphosphonate (1995), obesity 
epidemic, lifestyle changes and/or an increase in calcium and vitamin D intake [86].  
 
Vertebral fracture  
Vertebral fractures are the most common osteoporotic fracture with a prevalence of 15% 
in women aged 50-59 and 50% in women above age 85 [87] [88] [89]. Before age 65, prevalence 
of vertebral fractures is very similar or slightly higher in men compared to women. However, 
after age 65, the women to men ratio becomes close to that of hip fractures [90].  It has been 
found that vertebral fractures increase linearly with age and a good percentage of vertebral 
fractures occur in osteopenic older men and women [91].  These fractures are less well 
documented than hip fractures. To a lesser extent than hip fractures, vertebral fractures are 
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associated with an increased risk of death [92]. Vertebral fractures are important in individuals 
with osteoporosis because they tend to occur earlier and could indicate a decrease in bone 
strength perhaps because the vertebrae have more trabecular bone than cortical bone. Since 
trabecular bone is affected earlier than cortical bone in osteoporosis, vertebrae become at a high 
risk of fracturing [93].  
There are specific risk factors associated with vertebral fractures such as increase age, 
smoking, low milk consumption during pregnancy, low physical activity, previous fall, and 
aluminum-containing acid usage [94].  The risk of hip fracture was noted to be high in subjects 
with vertebral fracture [95]. Vertebral fractures have clinical implications. If detected, it is 
usually an indication to start therapy even if the T score is not below -2.5.  
Despite these important facts, most vertebral fractures are asymptomatic and are 
considered to be underdiagnosed. However, some anthropometric signs such as a decrease in 
height of more than 2 to 4 cm could hint to a possible spine fracture [96].  Worldwide, the 
prevalence of radiographic vertebral fracture is similar in men and women but clinical vertebral 
rates tend to be much higher than the hip fracture rates [81]. 
 
Distal forearm fracture 
The incidence of forearm fractures is greater in women than in men with about half 
occurring after age 65 [97]. Forearm fractures follow a different pattern compared to the hip and 
vertebral fractures. It is believed to increase between ages 45 and 60 because of the nature of the 
fall. After age 60, wrist fractures plateau and even decrease slightly perhaps because women tend 
to fall backwards or sideways with no attempt to break the fall with an outstretched arm [98]. 
The incidence in men is low and remains low throughout life.   
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Fracture risk prediction tool (FRAX) 
The WHO designed a country specific tool known as the fracture risk prediction tool 
(FRAX). FRAX has been shown to be a better predictor of fracture than T-scores alone. In 2008, 
the WHO added 11 risk factors to the femoral neck BMD as part of FRAX [99]. The 11 risk 
factors that were added are: age, sex, weight, height, previous fracture, parental history of hip 
fracture, current smoking, glucocorticoid use, rheumatoid arthritis, secondary osteoporosis, and 
alcohol 3 or more units per day. These factors were added to help in clinical assessment of 
patients because several studies have shown the importance of both clinical risk factors and 
BMD in predicting fractures (Figure 2)[100]. Furthermore, age has been found to increase the 
risk of fractures by 11 folds compared to BMD [101]. FRAX is a country specific tool that takes 
the mortality and hip fracture rate of the country into consideration. It has been developed in 
approximately 50 countries so far [102]. Using a poisson regression, the country specific 10 year 
probability of a major osteoporotic (hip, proximal humerus, clinical vertebral, forearm) fracture 
and hip fracture in men and women between 40 and 90 years of age can be calculated [101]. The 
risk factors included in FRAX were based on 12 prospective cohorts. These risk factors were 
subsequently validated in 11 other cohorts [103]. Nonetheless, it is important to note that FRAX 
is most effective in patients who are not getting treated for osteoporosis. Another FRAX 
limitation is that it does not include risk factors for falls which are known to be independent risk 
factors for nonvertebral fractures. Also, FRAX considers BMD only at the femoral neck. 
Therefore, BMD at other sites, biochemical indices, and computed tomography could provide 
extra information to better predict fractures [101]. 
 
 
 14 
1.2 SARCOPENIA 
1.2.1 Definition 
Although the concept of age associated loss of muscle mass has been known for centuries, it was 
not until 1989 that Rosenberg coined the term “sarcopenia”.  Sarcopenia was initially defined as 
the loss of muscle mass [104] [105]. The main purpose was to assign a name to this condition 
and promote research in the field. Many age related processes are believed to accelerate the loss 
of muscle mass. Nuclear apoptosis, oxidative stress, muscle fiber denervation, and reduction in 
satellite cell content and regenerative potential are some known etiologies [106] [107] [108]. 
Furthermore, sarcopenia has been linked to a decrease in functional capacity, increased risk of 
falls and fractures, inability to perform activities of daily living (ADL), loss of independence, 
and increase risk of death [109] [110] [111] [112]. Because of these age related consequences, 
some researchers and clinicians consider sarcopenia to be a geriatric syndrome.  
Nonetheless, it is important not to confuse sarcopenia with other geriatric syndromes 
such as cachexia and frailty. Cachexia is defined as severe wasting as a result of diseases. It’s 
usually due to inflammatory processes, insulin resistance, and muscle breakdown [113] [114]. 
Most cachectic older men and women are sarcopenic, but not all sarcopenic older individuals are 
cachectic. On the other hand, frailty is more physiological in nature and affects multiple systems 
at once. In frailty, the accumulation of subtreshold levels makes it difficult for the body to 
withstand stress. A considerable overlap exists between frailty and sarcopenia [115].  
In 2001, Morley et al. added muscle strength to the original definition of sarcopenia after 
numerous studies (mostly cross sectional) showed a relation between muscle mass and muscle 
strength [116] [117]. The main reason for adding muscle strength into the definition was because 
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lean mass, measured by DXA, underestimated the prevalence of sarcopenia [118]. Another 
reason is because muscle strength is associated with function and disability whereas muscle mass 
is not [119] [120] [121] [122]. Therefore, by adding muscle strength, sarcopenia becomes more 
clinically relevant. 
Subsequently, new definitions emerged under the sarcopenia syndrome umbrella adding 
muscle strength and/or physical performance to the muscle mass. The European Working Group 
on Sarcopenia in Older People (EWGSOP), the Foundation for the National Institutes of Health 
(FNIH), and the International Working Group on Sarcopenia each has its working definition. 
EWGSOP was founded in 2009 to come up with a clinical definition and diagnostic 
criteria for sarcopenia. This group defined sarcopenia as a syndrome characterized by the 
progressive and generalized loss of skeletal muscle mass and strength with a risk of adverse 
outcomes such as physical disability, poor quality of life, and death [123] [124]. The European 
working group recognized in addition to low muscle mass that there are many other factors that 
may contribute. The EWGSOP added muscle strength to its’ definition because the relationship 
between muscle mass and strength is not linear and therefore, considering muscle mass alone 
may not be of clinical relevance [124] [125].  
Similarly to EWGSOP, the FNIH definition includes both muscle mass and strength in 
its’ algorithm. The purpose of this group is to focus on the clinical aspect of sarcopenia. 
Therefore, FNIH put in place a project in order to identify criteria for clinically relevant 
weakness and low lean mass, and apply them to populations with high rates of functional 
limitations [126].  
The international working group on sarcopenia, which consists of a group of 
geriatricians, met in 2009 and proposed an alternative definition to Sarcopenia. These scientists 
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agreed that sarcopenia should be assessed in older individuals exhibiting signs of decline in 
physical function, strength, or health status. The group defined sarcopenia as follows: 
“Sarcopenia is the age-associated loss of skeletal muscle mass and function. Sarcopenia is a 
complex syndrome that is associated with muscle mass loss alone or in conjuction with increased 
fat mass” [127]. As seen in the definition, this group stressed the fact that increased fat mass 
should be part of the syndrome. Infiltration of fat into muscles results in a decrease in muscle 
quality and performance as seen in sarcopenic obesity. Even more, according to this group total 
body fat should be accounted for while evaluating muscle mass.  
These working groups consider sarcopenia to be a geriatric syndrome.  Nonetheless, other 
researchers believe that muscle mass, muscle strength, and physical function should be assessed 
separately because age-associated changes in muscle mass explain less than 5% of the variance 
in muscle strength change [128]. This indicates that there are other physiological factors other 
than muscle mass that could explain muscle weakness in older adults [129]. Manini et al. 
proposed to define loss of muscle mass and muscle weakness (dynapenia) independently since 
these two conditions have different etiologies [130]. Based on this concept, a dynapenia 
algorithm has been proposed. This algorithm is beyond the scope of this review. 
1.2.2 Pathophysiology 
Normal muscle is characterized by a homogenous distribution of type I and type II fibers. Type I 
fibers are more fatigue-resistance whereas type II fibers have glycolytic potential, lower 
oxidative capacity, and faster response [131]. 
As individuals age, they progressively experience a decrease in their muscle fiber size. 
This decrease has been shown to be fiber specific with larger decreases occurring in type II fibers 
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compared to type I [132]. Up to 40% of type II fibers are smaller in elderly subjects compared to 
younger subjects. Type I fibers do not change significantly with age [133] [134]. Despite a clear 
understanding of how the muscle fiber size changes with age, there is not enough evidence 
regarding the age associated loss of the number of muscle fibers [112]. Furthermore, the muscle 
fiber size becomes more heterogenous as men and women get older [135]. Extensive grouping of 
the same types of muscle fibers occur as seen under the microscope [136]. As part of the aging 
process, the muscle architecture deteriorates as well.  For instance, muscle fascicles tend to be 
shorter and attach less obliquely to its tendon which may lead to lower force production. Such 
age-related changes in fiber size and muscle architecture are observed in  sarcopenic individuals 
irrespective of the etiologies [137].  
1.2.3 Diagnostic tools 
Currently, a gold standard to diagnose sarcopenia does not exist because there is no consensus on 
the definition of sarcopenia. Several algorithms have been proposed by the different working 
groups to diagnose sarcopenia.  
The EWGSOP algorithm relies on a low lean mass plus either slowness or weakness. 
This group also categorized sarcopenia into stages based on severity: presarcopenic (low muscle 
mass), sarcopenia (low muscle mass with either slowness or weakness), and severe sarcopenia 
(low muscle mass with slowness and weakness) [115].  
On the other hand, the proposed algorithm of the International Working Group is based 
on having a low whole body or appendicular fat-free mass in combination with poor physical 
functioning. In other words, sarcopenia with limited mobility would be an indication for 
therapeutic intervention [127].  
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Irrespective of the algorithm used, there are many ways to measure muscle mass, muscle 
strength, and physical performance of older individuals. To measure muscle mass, 
anthropometric measures, computed tomography (CT), magnetic resonance imaging (MRI), dual 
energy X-ray absorptiometry (DXA), and bio impedance analysis are some available options 
[115]. Because CT and MRI distinguish fat from other soft tissues in the body, they are 
considered to be the gold standard for muscle mass assessment especially in research. However, 
the high radiation, high cost, and limited accessibility make it less used in clinical settings [115]. 
Anthropometric measurement is the simplest and cheapest method to assess body 
composition. It is achieved by measuring the height, weight, skin folds, waist circumference, etc. 
Using the height and weight, the body mass index (BMI) can be calculated to determine if 
individuals are underweight, normal, overweight, or obese. Although BMI is correlated with 
body fat, it does not provide information about body composition [115] [138]. 
Bioelectrical Impedance is another method used to assess body composition and muscle 
mass. Based on the concept that water conducts electricity and fat does not, total body water, fat-
free mass, fat mass, percentage of body fat and appendicular skeletal muscle mass measurements 
can be obtained. Gender and ethnic specific prediction equations have been modeled for adults 
and elderly, and reference values have been established [139] [140] [141] [142].  However, in 
this method, prediction equations are not always accurate, especially in overweight older adults 
[143]. 
Dual-Energy X-Ray Absorptiometry (DXA) is currently the most common and reliable 
technique to evaluate body composition. The whole body DXA provides fat and lean mass data 
[144]. However, there is more than one approach to interpret the results obtained by DXA. The 
two most adopted methods for assessing low muscle mass are the appendicular skeletal muscle 
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mass index and the residuals method. The appendicular skeletal muscle index is calculated by 
dividing the appendicular lean mass by height squared (ALM/h2). Low muscle mass is 
considered present if the calculated values are below certain established sex specific cutoffs 
[123] [145] [146]. Although it takes height into account, this method doesn’t adjust for total 
body fat. The residuals method is based on calculating the sex specific residuals of the regression 
of ALM (kg) on height (m) and whole-body total fat mass (kg).  Participants with residuals 
below the 20th percentile are considered to be sarcopenic [146]. The Framingham study 
published an article comparing these different methods. They found that the residuals method 
predicted the mobility limitations in both men and women better than simply dividing by height 
squared [147]. This seems to be in accordance with the International Working Group definition 
which includes total fat mass in its sarcopenia definition.  
Muscle strength can be measured by handgrip strength or knee flexion/extension [115]. 
Handgrip strength is a good measurement of muscle strength. Previous studies have shown that it 
correlates well with lower extremity muscle power, knee extension torque, and calf cross-
sectional muscle area [148]. It has also been associated with ADL and mortality [149] [150]. To 
determine muscle weakness, the EWGSOP recommended cutoffs of 30 Kg and 20 Kg for men 
and women respectively [148]. On the other hand, the FNIH project recommends the usage of 26 
kg and 16 kg for men and women respectively [126]. These cutoffs were determined based on 
the muscle strength data of nine collaborating studies: 1) Age, Gene/Environment Susceptibility-
Reykjavik Study [151], 2) Boston Puerto Rican Health Study [152], 3) Clinical Trials [153], 4) 
Framingham Heart Study [154], 5) Health, Aging, and Body Composition Study [155] 6) 
Invecchiare in Chianti [156], 7) Osteoporotic Fractures in Men Study [157] , 8) Rancho Bernardo 
Study [158], 9) Study of Osteoporotic Fractures [100]. Muscle strength could also be assessed by 
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the knee flexsion/extension. Although used in research settings, this method is not adopted in 
clinical practice because special equipment is needed [115]. This approach allows for isometric 
and isokinetic measurement of strength. Furthermore, muscle power which has been shown to be 
a better predictor of functional activities than muscle strength could be measured [159] [160] 
[161]. Nonetheless, more studies are needed in older people to establish clinical cutoffs.  
Physical performance can be measured by Short Physical Performance Battery (SPPB), 
usual gait speed, timed get-up-and-go test, and stair climb power test. SPPB and usual gait speed 
will be discussed. The SPPB assesses balance, gait, strength, and endurance. The SPPB is based 
on 4 components: stand with feet together, semi-tandem and tandem positions, time to walk 8ft, 
and chair stands [162]. The maximum score is 12 and sex specific cut-off points have been 
established [163]. SPPB is recommended by the international working group on sarcopenia 
[164].  
Usual gait speed is another commonly used measurement to assess physical performance. 
Gait speed, especially over a 6 meter course, has been linked to disabilities, adverse health 
events, and mortality [163] [165] [166]. The European and the international working groups on 
sarcopenia use 8m/s and 1m/s cutoffs respectively to determine slowness.  
1.2.4 Epidemiology 
The prevalence of sarcopenia varies based on the definition. Nonetheless, few studies have 
dichotomized sarcopenia based on specific criteria in order to calculate sarcopenia prevalence. 
For instance, using a cut-off point of two SD for the appendicular skeletal muscle mass index, 
the prevalence of sarcopenia ranged between 13% and 24% in those aged 65 to 70 years, and 
over 50% in those older than 80years. For individuals above age 75%, men had a higher 
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prevalence (58%) compared to women (45%) [145]. When total body fat was taken into account 
by using the residuals method, a higher prevalence of severe sarcopenia was observed in women 
compared to men. Severe sarcopenia was defined as a skeletal muscle mass index two standard 
deviations below young adult values [167]. Also, functional impairment and disability was 
greater in sarcopenic women compared to sarcopenic men [146] [167].  
Loss of muscle strength is correlated with the loss of muscle mass. Nonetheless, these 
two follow different patterns of decrease with age. The cross sectional area of the muscle 
decreases by 40% between ages 20 and 60 [168] [169] [170]. The muscle mass reduction is 
accelerated after the age of 50 [171]. Men usually experience larger decreases (14.8%) in 
appendicular lean mass compared to women (10.8%) [172]. These gender specific changes in 
muscle mass have been suggested to be hormonal in nature [173]. The decrease starts to be 
noticeable after the age of 30. Muscle mass decreases by 3 to 8% per decade, with acceleration in 
muscle loss after age 60 [174]. On the other hand, muscle strength decreases by 20 to 40% with 
age and can reach up to 50% in the oldest of the old [175] [176] [177] [178]. Men have greater 
decrease in muscle strength compared to women which is usually explained by the fact that men 
have higher baseline values. The decline in muscle mass has been associated with a decline in 
muscle strength. However, the strength decline is more rapid than the mass decline suggesting 
that there is a decrease in muscle quality as individuals age [124].  
Studies looking at longitudinal changes in muscle strength and mass are lacking. 
Goodpaster et al. followed older adults for a duration of three years. Findings showed that white 
and black men experience a 3.4% and 4.1% decline in muscle strength respectively. On the other 
hand, there is a 2.6% and 3.0% decline in muscle strength for white and black women 
respectively. Annualized change in lean mass was about 1% in older adults irrespective of 
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gender or race. In another study, Newman et al. studied the changes in weight and lean mass. 
Findings showed that older persons lose both lean mass and fat mass with age. However, more 
lean mass was conserved compared to fat mass with changes in weight. Furthermore, more lean 
mass is lost with weight loss favoring sarcopenia [179].  
Sarcopenia is linked to many health outcomes such as loss in functional capacity, loss of 
independence, and falls [110] [111]. In this review, the main consequence of sarcopenia we are 
interested in studying, is its effect on the bone strength. Therefore, the common etiologies of 
muscle and bone deterioration as well as the crosstalk between these two tissues will be 
elucidated in the next section. 
1.3 MUSCLE BONE ETIOLOGIES 
Muscles and bones are neighboring tissues with close ties and are both derived from a common 
mesenchymal precursor [2]. Muscles contribute to bone development during embryogenesis 
[180]. Bones have been shown as well to play a role in fetal myoblast survival and limb muscle 
growth[181]. This crosstalk between muscles and bones does not occur only during fetal 
development but is a lifelong process [3]. Throughout life, muscles and bones seem to follow the 
same decreasing pattern. The loss of muscle mass and bone mass has been shown to be coupled 
and part of the same functional unit [182]. However, the etiologies behind this synchronized 
decrease in the bone and muscle tissues are not very well understood. Some of these risk factors 
are believed to be genetic in nature whereas others physiological and hormonal. Pleiotropy, 
mechanotransduction, and endocrine roles are the main etiologies responsible for the coordinated 
and progressive deterioration of the musculoskeletal system throughout life [3]. 
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1.3.1 Pleiotropy 
It is believed that genes could play a role in the simultaneous deterioration of muscles and bones. 
Efforts are being made to discover these pleiotropic genes with the hope of treating osteoporosis 
and sarcopenia together. The pleiotropic effect on the musculoskeletal system could be direct or 
indirect [183]. Direct pleiotropy is when one gene affects both bone and muscle phenotype. 
However, in most instances, the pleiotropy is indirect and impacts muscles and bones through 
systemic control factors[183].  
Bone mass and geometry have been previously linked to genetic determinants [184-186]. 
Furthermore, muscle mass and strength has been shown to be under genetic control [187]. After 
finding a high genetic correlation between bone geometric parameters and muscle mass, 
scientists became interested in discovering genes that could explain the synchronized 
deterioration in bones and muscles [188].  
Myostatin, coded by the Growth Differentiation factor gene (GDF8), is a member of the 
Transforming Growth Factor (TGF-B) superfamily. During muscle disuse, myostatin is secreted 
from skeletal muscle cells into the blood and act on neighboring tissues [189]. This systemic 
factor influences simultaneously bone and muscle metabolism. In animal models, myostatin 
deficiency was associated with greater cortical bone mineral content and with a hypermuscular 
phenotype [190].  
Vitamin D receptor (VDR) gene is another pleiotropic gene that affects the 
musculoskeletal system. VDR is known to regulate bone metabolism and homeostasis. In 
addition to its action on the bones, few studies demonstrated that VDR is expressed in skeletal 
muscles.  By binding to these receptors, vitamin D was shown to increase muscle strength[183]. 
The effect of the single-nucleotide polymorphisms (SNPs) within this gene were associated with 
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decreased vertebral area, increased risk of vertebral fractures, femoral neck width narrowing, and 
increased lean mass and muscle strength [191] [192] [193] [194].  
The Insulin-like Growth Factor (IGF-1), coded by the IGF-1 gene, is a systemic hormone 
involved in the development and repair of bones. The mechanical load of muscles on bones 
results in an increase in IGF-1 leading to osteocytes differentiation and bone formation [195]. 
Therefore, with age, the decrease in IGF-1 leads to attenuated response of the bones to the 
mechanical load of muscles.  Evidence of IGF-1 effect on cortical bones has been well 
established. The action of IGF-1 is not unidirectional. It also induces muscle hypertrophy by 
acting on its receptor [196]. 
Low density lipoprotein receptor related protein 5 (LRP5), coded by the pleotropic gene 
wnt, is another systemic factor that is linked to both bones and muscles. In addition to being 
associated with BMD in humans, LRP5 mutations in mice resulted in a greater skeleton strength 
[197] [198] [199]. Furthermore, the LRP5 knockout mice demonstrated a lack of response to 
mechanical stimuli [200]. Similarly to the growth hormone, LRP5 may play a role in the 
mechanical response of bones to muscles. Whereas IGF-1 plays a role in sensing the mechanical 
load of muscle on bones, LRP5 consists more of responding to the load by producing new 
periosteal bone [200]. Mechanotransduction will be discussed further in the next section. 
1.3.2 Mechanotransduction 
The bone is an organ that senses the mechanical pressure of muscles. The muscle load is 
important not only to maintain the strength of the bones but also for fracture repair [183] [201]. 
The anabolic effect on the bones could be explained by a direct process (mechanotransduction) 
or indirect one (endocrine regulation such as IGF1 and LRP5 discussed earlier) [2].  The pressure 
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of the muscles on the bones is sensed by osteocytes. The translation of this mechanical signal to 
a cellular one is known as mechanotransduction. Osteocytes form a network of cells which are 
interconnected. This network of cells have the capability of sensing the load of muscles [11]. As 
a result, osteocytes send signals to recruit other cells facilitating the bone remodeling as well as 
matrix formation [202, 203]. The osteocytes also stimulate the expression of molecules such 
IGF-1 as previously discussed [204, 205]. Also, osteocytes have been shown to regulate 
osteoblast and osteoclast activities [206, 207]. Initially, studies conducted on tennis players have 
shown that the dominant arm had a higher BMD [208-210]. This fact intrigued scientists, and 
subsequent studies were conducted showing associations between muscle mass and strength, and 
BMD. As discussed in the sarcopenia section, muscle mass and strength decrease throughout life. 
This decrease is believed to result in a concomitant decrease in BMD and quality.  
In fact, a decrease in muscle mass and strength have been previously associated with low 
BMD[211] [212] [213] [214] [215] [216]. Other studies also showed that older individuals with 
sarcopenia had poorer quality of bones [217] [218]. 
1.3.3 Endocrine roles 
Muscles and bones are endocrine organs that secrete paracrine hormones [3]. Humoral factors, 
such as IGF-1 and FGF-2, are believed to play a major role in the muscle bone cross talk. These 
growth factors secreted by the muscle have receptors on the periosteum which is located at the 
muscle bone interface [219]. Other myokines could also impact indirectly the bones. For 
instance, interleukin 6 (IL-6) and leukemia inhibitory factor (LIF) have been previously 
associated with resorption and formation of bones respectively.  Il-6 is a cytokine produced at 
high levels by the muscles, especially after resistance exercise [220]. Initially, it was believed 
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that the mechanism by which Il-6 impacts is through insulin production. Insulin was thought to 
bind to receptors on the osteoblasts and blunt the resorptive activity of PTH [221] [222]. 
However, more recent in vitro studies showed that Il-6 inhibits IGF-1 production and 
consequently, decrease bone formation [223]. 
Growth hormone (GH) and IGF-1 discussed in the pleiotropy section, exert important 
anabolic effects on both muscles and bones. With age, the GH/IGF-1 signaling pathway 
decreases in efficiency. This results in a decrease in muscle size and strength, a reduction in 
protein synthesis, and increased cell apoptosis. Furthermore, abnormalities in the GH/IGF-1 
signaling leads to a decrease bone formation due to impaired osteoblasts and bone cell apoptosis 
(Figure 3) [224].  
Furthermore, some animal studies have found that the growth factor Indian hedgehog 
(Ihh) produced by chondrocytes is responsible for fetal myoblast survival and limb muscle 
growth Also, myogenic progenitor cells and muscle satellite colonization have the ability to 
differentiate into chondrocytes or osteoblast. [181]. This shows that the cross talk between 
muscles and bones starts early during fetal development and continues throughout life.  Muscles 
and bones also act as endocrine target organs, which are under the influence of similar hormones 
such as testosterone and estrogen. Estradiol is the main sex steroid responsible for bone 
resorption in men and women, and is also responsible for enhancing the muscle contractions on 
bones [225] [226]. Androgens affect the muscle mass and strength as well as the trabecular bone 
formation [227]. Therefore, as men and women age, the decrease in testosterone and estrogen 
may put men and women at a higher risk for sarcopenia and osteoporosis.  
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The age-related decrease in hormones, the mechanotransduction effect of sarcopenia on 
bones, and pleiotropy are important etiologies of sarcopenia and osteoporosis combined. More 
research is needed in this field to elucidate the exact mechanisms responsible for both conditions. 
Common risk factors to both osteoporosis and sarcopenia are not known. Furthermore, 
the effect of both osteoporosis and sarcopenia on fracture risk is unclear. The aims of this 
dissertation is to elucidate these gaps in order to have a better understanding of the common 
etiologies of sarcopenia and osteoporosis. 
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2.0  SPECIFIC AIMS 
2.1 IMAGING DIAGNOSTIC TOOLS 
2.1.1 Specific aim 1 
We aim to: 1) assess the risk of various types of fractures in older men by areal and volumetric 
BMD at multiple sites and 2) compare the fracture predictability of the areal and volumetric 
femoral neck and spine BMD 
2.2 MUSCLE BONE CROSSTALK 
2.2.1 Specific aim 2 
We aim to: 1) determine the association between appendicular lean mass and measures of 
skeletal size, density, and strength, and 2) study the association between grip strength, and 
peripheral and central QCT skeletal parameters and 3) compare QCT parameters of participants 
across leg power quartiles 
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2.2.2 Specific aim 3 
We aim to show that: 
1) men and women with sarcopenia alone are at higher risk of having non-spine fractures 
compared to normal men and that 2) the combined effect of low bone mass and sarcopenia puts 
older men and women at a much higher risk of having non spine fractures.  
 
The Osteoporotic Fractures in Men (MrOS) study will be used to answer the first two 
aims. Data from the Study of Osteoporotic Fractures (SOF) and MrOS will be used to answer the 
third aim.  
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3.1 ABSTRACT 
Although many studies have examined the association between low bone mineral density (BMD) 
and fracture risk in older men, none have simultaneously studied the relationship between 
multiple BMD sites and risk of different types of fractures. Using data from the Osteoporotic 
Fractures in Men study, we evaluated the association between areal BMD (aBMD) by dual-
energy X-ray absorptiometry (DXA) and volumetric BMD (vBMD) by quantitative computed 
tomography (QCT) measurements, and different types of fractures during an average of 9.7 years 
of follow up. Men answered questionnaires about fractures every 4 months (>97% completions). 
Fractures were confirmed by centralized review of radiographic reports; pathological fractures 
were excluded.  Risk of fractures was assessed at the hip, spine, wrist, shoulder, arm, 
rib/chest/sternum, pelvis/coccyx, leg, hand/finger, skull/face, ankle/foot/toe, and any non-spine 
fracture. Age and race adjusted Cox proportional-hazards modeling was used to assess the risk of 
fracture in 3301 older men with both aBMD (at the femoral neck (FN) and lumbar spine) and 
vBMD (at the trabecular spine and FN, and cortical FN) measurements, with hazard ratios (HRs) 
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expressed per standard deviation (SD) decrease. Lower FN and spine aBMD were associated 
with an increased risk of fracture at the hip, spine, wrist, shoulder, rib/chest/sternum, arm, and 
any non-spine fracture (statistically significant HRs per SD decrease ranged from 1.24 – 3.57). 
Lower trabecular spine and FN vBMD were associated with increased risk of most fractures with 
statistically significant HRs ranging between 1.27 and 3.69.  There was a statistically significant 
association between FN cortical vBMD and fracture risk at the hip (HR=1.55) and spine sites 
(HR=1.26), but no association at other fracture sites. In summary, both lower aBMD and vBMD 
were associated with increased fracture risk. The stronger associations observed for trabecular 
vBMD than cortical vBMD may reflect the higher rate of bone turnover in the trabecular 
compartment.  
3.2 INTRODUCTION 
With the increase in the average age of the world population, the number of osteoporotic 
fractures likely will increase [81]. Worldwide, the total disability adjusted life years (DALYs) 
lost attributed to fractures was about 58 million in 2008 [228]. 
Mortality and morbidity are two major consequences of osteoporosis, primarily due to 
hip fractures [65]. However, the public health impact of osteoporotic fractures is not limited to 
hip fractures. In Medicare enrollees, while hip fractures had the highest excess cost, many types 
of fractures were associated with higher health care expenditures[65] [229].  Low bone mineral 
density (BMD) is an established risk factor for fractures. Indeed, low BMD has been linked to 
most fractures in women except for the heel, ankle, and face [230]. To our knowledge, a similar 
analysis has not been carried out in older men. We previously showed that low areal BMD 
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(aBMD) was related to all non-spine fractures and hip fractures in older men [231] [232]. 
Furthermore, Black et al. reported the relationship between trabecular and cortical FN volumetric 
BMD (vBMD) and hip fracture [52]. However, the association between multiple measures of 
BMD and risk of different types of fractures remains unexplored.  
Thus, the purpose of the current analysis was to assess the risk of multiple types of 
fractures in older men by aBMD and vBMD at multiple skeletal sites. A second aim was to 
compare fracture predictability of different BMD measurements. 
3.3 MATERIALS AND METHODS 
The Osteoporotic Fractures in Men study (MrOS) is a multicenter prospective cohort study 
designed to identify risk factors for osteoporosis and osteoporotic fracture. This study consists of 
5,994 older men recruited from six sites across the United States (Birmingham, AL; 
Minneapolis, MN; Palo Alto, CA; Pittsburgh, PA; Portland, OR; and San Diego, CA) from 
March 2000 to April 2002 [233] [157]. To be eligible, men needed to be age 65 years or older, be 
able to walk without assistance from another person, and have reported no bilateral hip 
replacement. Human subjects’ approval was obtained at all sites with written informed consent 
obtained from all participants.  The first 650 men and all nonwhite men enrolled at each clinical 
site were referred for quantitative computer tomography (QCT) scans of the hip and lumbar 
spine as part of their baseline visit, for a total of 3786 men (63% of the MrOS cohort). Out of 
these participants, 134 had unusable QCT images because of insufficient number of images, 
interference from metal, calibration standard not visible, or unrecorded cause. From the 
remaining participants, 3,305 had complete aBMD and vBMD measurements. We restricted 
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analyses to 3,301 after excluding 4 participants with pathological fractures. Except for a higher 
proportion of minorities (12.9% vs 10.5%), the characteristics of men in the vBMD subset were 
similar to the overall population of men. 
 
Areal Bone Mineral Density (aBMD) measurement 
Femoral neck (FN) BMD (g/cm2) and lumbar spine (LS) (L1-L4) BMD (g/cm2) were 
measured using dual-energy X-ray absorptiometry (DXA) with the Hologic QDR 4500 (Bedford, 
MA). Details of the measurement and densitometry procedures have been published elsewhere 
[234] [231]. Standardized procedures for positioning the participants and analyzing the scans 
were followed for all scans. All DXA operators were centrally certified based on an evaluation of 
their scanning and analysis techniques. Cross-calibration studies performed before the baseline 
MrOS visit found no linear differences across the scanners, and the maximum percentage 
difference in mean total LS BMD between scanners was 1.4%. To assess longitudinal 
performance of the scanners, an anthropometric spine phantom was scanned daily and a hip 
phantom weekly at each clinical center. The right hip was scanned unless there was a fracture, 
implant, hardware, or other problem, in which case the left hip was scanned. The T-score was 
calculated using the National Health and Nutrition Examination Survey III reference database 
[28]. Young Caucasian women were used as the reference population as recommended by the 
International Society for Clinical Densitometry (ISCD) [29]. 
 
Volumetric BMD measurement 
Volumetric BMD (g/cm3) of the LS and hip regions was measured using QCT [53, 235]. 
As previously described, images were acquired using a GE Prospeed (Birmingham), GE Hispeed 
Advantage (Minneapolis), Philips MX-8000 (Palo Alto), Siemans Somatom +4 (Pittsburgh), 
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Philips CT-Twin (Portland), Toshiba Acquilion (Portland) site, or Picker PQ-5000 (San Diego). 
All QCT scans were transferred to the University of California at San Francisco for processing 
and central review. Image processing was performed using published methods [53, 236]. Each 
participant's scan included a calibration standard of three hydroxyapatite concentrations (150, 75, 
and 0 mg/cm 3; Image Analysis). Images were converted from the native scanner Hounsfield 
Units (HU) to equivalent concentration (g/cm3) of calcium hydroxyapatite contained in the 
calibrations standard.  
QCT measurement of the LS was obtained using an anatomical region 5 mm above the 
L1 superior endplate to 5 mm below the L2 inferior endplate. LS images were acquired using a 
setting of 120 kVp, 150 mA, 1-mm slice thickness, and 512 x 512 matrix in spiral reconstruction 
mode. To derive trabecular vBMD, previously described analytical techniques were employed to 
orient the vertebrae so that the vertebral cross-sections were obtained in a plane parallel to the 
two endplates and to segment the vertebral body from the scans. Vertebral trabecular BMD was 
determined in a region containing most of the trabecular bone in the vertebral body. This QCT 
protocol has been described previously [237].  
To measure vBMD at the femoral neck, a QCT scan of the pelvic region (from the 
femoral head to 3.5 cm below the lesser trochanter) was acquired at settings of 80 kVp, 280 mA, 
3-mm slice thickness, and 512 × 512 matrix in spiral reconstruction mode [235]. 
Regions of interest (ROI) in the left proximal femur were identified in QCT images 
reformatted along the neutral axis of the FN. The periosteal boundary of the femur was 
determined with a threshold-based region growing algorithm. Using this boundary, the cross-
sectional area in each slice along the neutral axis of the FN between the proximal FN and the 
lateral edge of the trochanter was calculated, and the minimum and maximum areas were 
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determined. The FN ROI was defined as the portions of the neck extending from the slice with 
minimum cross-sectional area (medial boundary) to a point 25% of the distance toward the 
maximal cross-sectional area. Integral volume of the ROI was computed as the total volume 
within the periosteal boundary. A trabecular volume of the ROI was obtained by applying an 
erosion process to the integral volume to retain the same shape in a region fully contained within 
the medullary space. The cortical volume was then defined by applying a threshold of 0.35 g/cm3 
to all voxels between the periosteal boundary and the outer boundary of the trabecular volume. 
Volumetric BMD for trabecular and cortical compartments was computed over all voxels in the 
respective volumes.  
 
Clinical fractures ascertainment 
Questionnaires were mailed to participants every 4 months to identify fractures, with 
more than 97% completion. If a fracture was reported, the participants were contacted to obtain a 
copy of the radiographic report. All clinical fractures were confirmed by central review of 
radiographic report during an average of 9.4 years (0-13.7) from study enrollment until February 
2014. Clinical spine fractures were confirmed by radiologist review of clinical images (x-ray, 
MRI, etc.) and in comparison to study lateral spine radiographs collected at the baseline visit. 
Fractures due to any level of trauma (minimal, moderate, and severe) were included since they 
have been previously associated with low BMD [238].  Multiple fracture sites were studied 
including hip, spine, wrist, shoulder, pelvis/coccyx, rib/chest/sternum, skull/face, hand/finger, 
ankle/foot/toe, arm, and leg.  
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Statistical methods 
The analytical cohort consisted of 3301 older men with both complete aBMD and vBMD 
measurements. Age and race adjusted Cox proportional hazards modeling with 95% confidence 
intervals (CI) was used to calculate hazard ratios (HR) per one standard deviation (SD) decrease 
in aBMD and vBMD. A logistic regression was used to study receiver operating characteristic 
(ROC) curves of different BMD measurements for the major osteoporotic fractures which consist 
of the hip, spine, shoulder, and wrist. The ability of BMD measurements to predict fracture risk 
was assessed by the area under the curve (AUC) or C statistics. Statistical comparison was 
conducted between different AUC curves to determine which one most strongly predicts fracture 
risk. Statistical analyses were performed using SAS 9.3 (SAS Institute, Inc., Cary, NC). 
3.4 RESULTS 
The average age of the men was 73.5 years with a mean FN T-score of – 0.61 (Table 1). Over a 
mean of 9.7 years, 580 men experienced 748 fractures, 305 of which were major osteoporotic 
fractures. On average, men were overweight and primarily white race.  
 
BMD and Fracture risk 
Lower LS and FN aBMD were associated with a statistically significantly higher risk of 
fracture at the hip, spine, wrist, shoulder, rib/chest/sternum, and arm (Table 2). The HRs ranged 
from 1.31 (rib/chest/sternum) to 2.74(hip) per one SD decrease in FN aBMD, and between 1.24 
(rib/chest/sternum) and 3.56 (spine) per one SD decrease in total spine aBMD. The associations 
with ankle/foot/toe (spine), hand/finger (FN), pelvis/coccyx (spine) were borderline significant. 
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There was no relationship between aBMD, and leg and skull/face fractures. For all non-spine 
fractures, one SD decrease in LS aBMD and FN aBMD was associated with a 31% and 53%, 
respectively, increase in fracture risk.  
Trabecular vBMD of both the LS and FN were also related to many fractures, Table 2.  In 
particular, one SD decrease in trabecular vBMD of the LS was associated with almost a 4-fold 
increase in clinical spine fractures. Lower trabecular vBMD at both the spine and hip was also 
associated with a higher risk of hip, wrist, shoulder, rib/chest/sternum, ankle/foot/toe, arm and 
leg fractures. The association between trabecular vBMD at the LS and FN and any non-spine 
fractures was similar in magnitude to the association between aBMD and any non-spine fracture. 
In contrast, FN cortical vBMD was statistically significantly associated with hip and clinical 
spine fractures, but there was no association between cortical vBMD and fractures at other 
fracture locations. There was a modest relationship between FN cortical vBMD and any non-
spine fracture, HR=1.13 (1.04, 1.24) 
There was evidence of site specificity where a strong relationship was found for LS 
aBMD and spine fractures (HR=3.57) and between FN aBMD and hip fractures (HR=2.74). Site 
specificity was present as well between LS vBMD and spine fracture (HR=3.69). The effect size 
was the highest for spine fracture and lower for other fracture types. On the other hand, 
specificity between FN vBMD and hip fracture was not as robust since the calculated effect sizes 
were similar if not identical, such as in the case of clinical spine (Table 2). 
The results of the AUC comparisons are shown in Table 3. FN aBMD (AUC=0.76) had a 
higher predictability of hip fractures compared to cortical FN vBMD (AUC=0.69). Furthermore, 
FN aBMD had a better predictability of hip fractures compared to trabecular FN vBMD 
(AUC=0.72). Nonetheless, there was no difference in AUCs between trabecular and cortical FN 
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vBMD for hip fractures. Trabecular vBMD of LS had better predictability of spine fractures 
compared to spine aBMD. 
3.5 DISCUSSION 
The risk of most types of fractures is higher with lower areal and volumetric BMD. Stronger 
associations were seen with trabecular vBMD compared to cortical vBMD. Furthermore, there 
was high specificity between BMD site and fracture type, especially for aBMD. Several fracture 
types were for the most part unrelated to low BMD, including fractures that occurred at the hand 
or finger; pelvis or coccyx; skull or face. Results showed that FN aBMD is a better predictor of 
hip fractures compared to trabecular and cortical FN BMD. However, trabecular vBMD of LS 
had better predictability of spine fractures compared to areal spine BMD.   
Both low aBMD and vBMD were associated with an increased risk of different types of 
fractures. A previous study conducted in women has shown an increase of almost all types of 
fractures with low aBMD [230]. With the exception of spine fractures, which have an apparently 
stronger association in men (HR=3.57 in men, HR=2.06 in women for one SD decrease in LS 
aBMD), the risks of different type of fractures were roughly the same across gender.  
Areal BMD is a strong independent risk factor for fractures in men[67]. Our results are 
consistent with previous MrOS reports which found strong associations between hip BMD and 
nonvertebral fractures (especially hip) in older men [232] [239]. The current analysis extends 
these findings to most fracture types. 
On the other hand, the relationship between trabecular and cortical vBMD with fracture 
risk is less well understood.  We showed that trabecular vBMD of LS and FN were both 
 40 
associated with many types of fractures. In contrast, cortical vBMD was related to hip and spine 
fractures only. Although hip fractures are attributed to both cortical and trabecular bone loss, 
very few studies have examined the association  between vBMD and hip fractures [52] [93]. Our 
results for hip fracture are consistent with an earlier MrOS report with shorter follow-up. 
The stronger associations observed for trabecular vBMD compared to cortical vBMD 
may be explained by the higher rate of bone turnover in the trabecular compartment compared 
with cortical compartment. Trabecular and cortical compartments have different metabolic 
activities with the former being more active contributing to greater rates of bone loss [93]. With 
age, trabeculae become thinner, the number of trabeculae decreases, and trabecular spacing 
increases. The cortical compartment also undergoes age-related changes such as increase in 
porosity, but we were unable to capture cortical porosity with our measurements [240]. Although 
both compartments demonstrate microarchitecture changes, the different effect sizes may be 
explained by the trabecular and cortical bone-specific proportions. For instance, the vertebral 
body consists of largely trabecular bone with a thin layer of cortical bone [93]. The majority of 
the vertebral body strength is maintained by trabecular bone. Therefore, this may explain why 
trabecular BMD was more highly associated with spine fractures compared to cortical BMD.   
Cortical FN BMD was associated with only hip and spine fractures perhaps because 
cortical bone at least at the hip plays a key role at this site relative to the other fracture locations. 
Yoshikawa et al. demonstrated that the loss of bone occurs more on the superior aspect of the FN 
[241]. At the FN, the superior region of the cortical bone is thinner compared to its inferior 
region. With age, thinning of the superior region occurs, and compromises the capacity of the 
femur to absorb energy independently of osteoporosis. The thinning of this region with age may 
reflect a lower mechanical load. Since most hip fractures result from a fall, the impact on the hip 
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reverses the stress pattern leading to increase in compressive stress on the superior neck which is 
mainly cortical bone [242]. This may explain why low cortical FN was associated with an 
increased risk of hip fractures. Although loss of cortical bone occurs at other sites as well, the 
biomechanics of fractures as well as the proportion of cortical bone in individual bones may 
explain why we did not detect statistically significant associations with other fracture sites.  Risk 
of spine fractures was also higher with lower cortical FN BMD. Although the trabecular bone is 
known to constitute the majority of the vertebra, the cortical thickness influences vertebral 
strength mostly when the trabecular bone volume gets low [243-245]. Since our cohort consists 
of elderly men with low trabecular spine BMD (0.11 g/cm3), it is likely that the cortical bone 
influenced the vertebral strength and hence, spine fracture risk. 
The risk of hip fracture was higher with low FN aBMD compared to the trabecular and 
cortical vBMD. Indeed, FN aBMD was a better predictor of hip fractures compared to trabecular 
and cortical FN BMD. This finding could be explained by the fact that areal FN aBMD is not 
compartment specific and comprises both trabecular and cortical bone. Areal BMD is known to 
highly correlate with and account for 60-70% of the bone strength [42, 246]. In agreement with 
our findings, a previous study showed that the QCT parameters’ prediction of hip fracture was 
not improved compared to aBMD [52]. On the other hand, our findings showed that trabecular 
spine BMD was a better predictor of spine fractures compared to areal spine BMD. In their 
study, Wang et al also demonstrated that vBMD improved vertebral fracture risk assessment 
compared to aBMD [247]. Here, although areal spine comprises both compartments, the fact that 
the trabecular proportion of the vertebrae is much greater than the cortical proportion may 
explain the higher predictability of the trabecular vBMD at the LS. Furthermore, the artifacts 
seen on DXA scans may explain the lower predictability of areal spine BMD.  
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There are several strengths to our study. MrOS is a multicenter prospective study 
examining potential risk factors for fractures in a large population of older men. We were able to 
examine the association of both aBMD and vBMD including both the trabecular and cortical 
compartments and fractures risk in the same group of men. However, there are also several 
limitations. Most importantly, the men were primarily Caucasians and our results may not be 
generalizable to men of other race/ethnic groups. In addition, the number of specific fractures 
varied by site limiting our power to detect an association for fracture locations that were 
uncommon. To assess predictability of fractures, we used the widely used method of area under 
the curve. However, there are other methods based on the integrated sensitivity and specificity, 
and on reclassification tables that may provide additional information compared to AUC [248]. 
To conclude, low aBMD and trabecular vBMD were associated with an increased risk of 
most fractures. There was no evidence that trabecular vBMD was superior to aBMD in 
predicting hip fractures, which was not the case for spine fractures. Although QCT provides a 
compartment specific assessment of bone, it has several disadvantages such as its high cost, 
radiation exposure, and not being readily clinically accessible. With the exception of spine 
fractures, QCT does not appear to add additional information to fracture risk assessment once 
aBMD from DXA is known. Future studies might be needed to understand further the advantage 
of QCT over DXA in predicting spine fractures. In addition, screening for osteoporosis using 
DXA may help in preventing multiple types of fractures.  
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3.6 TABLES AND FIGURES 
Table 3.6.1. Baseline characteristics 
Characteristics Values Range 
Age (yrs) 
 BMI (kg/m2) 
Race, n(%) 
 White 
 African American 
   Asian 
   Hispanic 
   Other 
Previous fracture, n(%) 
73.5(5.9) 
27.3 (3.8) 
 
2,878 (87.7) 
170 (5.2) 
121 (3.7) 
91 (2.8) 
41(1.2) 
1791 (54.3) 
65-100 
17.2 – 50.7 
Areal BMD (g/cm2) 
Total spine 
Total hip 
        Femoral neck 
   Femoral neck T-score 
 
1.07 (0.19) 
0.96 (0.14) 
0.78 (0.13) 
-0.61 (1.06) 
 
0.51-2.10 
0.53-1.45 
0.35-1.49 
-4.25-5.27 
Volumetric BMD (g/cm3) 
Femoral neck 
Cortical bone 
Trabecular bone 
 
 
0.53 (0.06) 
0.07 (0.04) 
 
 
0.33-0.93 
-0.06-0.29 
Total femur 
Cortical bone 
Trabecular bone 
 
0.52 (0.05) 
0.10(0.04) 
 
0.35-0.81 
-0.01-0.25 
Total spine 
Trabecular bone 
 
0.11 (0.04) 
 
0.01-0.35 
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Table 3.6.2. Areal and volumetric BMD and risk of various types of fractures (FX): age and race adjusted hazard ratios (HR) 
and 95% confidence intervals (CI) HR per one SD decrease in BMD 
 
 
 
  Areal BMD Volumetric BMD 
 N of FX Total spine Femoral neck Trabecular spine Cortical FN Trabecular FN 
Hip 119 1.29 (1.07, 1.56) 2.74 (2.19, 3.42) 1.80 (1.43, 2.26) 1.55 (1.28, 1.87) 1.74 (1.41, 2.13) 
Clinical Spine 99 3.57 (2.78, 4.58) 1.95 (1.54, 2.47) 3.69 (2.78, 4.90) 1.26 (1.02, 1.55) 1.74 (1.39, 2.18) 
Wrist 46 1.43 (1.04, 1.97) 1.82 (1.30, 2.55) 1.46 (1.04, 2.05) 1.28 (0.95, 1.72) 1.74 (1.25, 2.43) 
Shoulder 41 1.63 (1.17, 2.28) 1.88 (1.31, 2.70) 1.73 (1.18, 2.54) 1.14 (0.83, 1.56) 1.46 (1.05, 2.04) 
Rib/chest/sternum 141 1.24 (1.04, 1.48) 1.31 (1.09, 1.57) 1.27 (1.05, 1.54) 1.05 (0.88, 1.24) 1.26 (1.06, 1.51) 
Ankle/foot/toe 91 1.21 (0.97, 1.51) 1.18 (0.94, 1.47) 1.35 (1.06, 1.73) 0.99 (0.80, 1.22) 1.26 (1.01, 1.58) 
Arm 55 1.68 (1.25, 2.27) 1.55 (1.14, 2.09) 1.75 (1.26, 2.44) 1.09 (0.83, 1.43) 1.35 (1.01, 1.81) 
Hand/finger 52 1.20 (0.89, 1.60) 1.30 (0.97, 1.76) 0.94 (0.71, 1.24) 1.08 (0.82, 1.43) 1.28 (0.95, 1.73) 
Leg 43 1.22 (0.88, 1.68) 1.32 (0.94, 1.84) 1.56 (1.08, 2.25) 1.06 (0.78, 1.44) 1.54 (1.10, 2.16) 
Pelvis/coccyx 34 1.38 (0.96, 1.99) 1.11 (0.78, 1.59) 1.45 (0.97, 2.17) 0.86 (0.62, 1.20) 1.29 (0.90, 1.85) 
Skull/face 27 1.17 (0.78, 1.75) 1.09 (0.73, 1.63) 0.91 (0.61, 1.34) 1.08 (0.73, 1.59) 1.06 (0.71, 1.57) 
Any non-spine fracture* 524 1.31 (1.19, 1.43) 1.53 (1.38, 1.68) 1.39 (1.26, 1.54) 1.13 (1.04, 1.24) 1.34 (1.22, 1.47) 
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Table 3.6.3. Age and race adjusted area under the curve (AUC) comparisons for all types of fractures 
 
 
Significant with p<0.05: a total spine vs femoral neck, b total spine vs trabecular spine, c total spine vs cortical FN, d total spine vs 
trabecular FN, e femoral neck vs trabecular spine, f femoral neck vs cortical FN, g femoral neck vs trabecular FN, h trabecular spine 
vs cortical FN, i trabecular spine vs trabecular FN, j cortical FN vs trabecular FN 
  Areal BMD Volumetric BMD  
 N of FX Total spine Femoral neck Trabecular spine Cortical FN Trabecular FN p-value 
Hip 119 0.67 0.76 0.71 0.69 0.72 a,b,d,e,f,g, 
Clinical Spine 99 0.72 0.70 0.79 0.63 0.69 b,c,e,f,h,i,j 
Wrist 46 0.51 0.58 0.59 0.57 0.64 d 
Shoulder 41 0.74 0.75 0.75 0.72 0.74  
Rib/chest/sternum 141 0.62 0.59 0.61 0.59 0.60  
Ankle/foot/toe 91 0.59 0.58 0.60 0.59 0.62  
Arm 55 0.64 0.60 0.66 0.60 0.62  
Hand/finger 52 0.57 0.58 0.57 0.58 0.59  
Leg 43 0.58 0.61 0.64 0.59 0.65  
Pelvis/coccyx 34 0.69 0.66 0.68 0.66 0.67  
Skull/face 27 0.59 0.62 0.59 0.58 0.59 f 
Any non-spine fracture* 524 0.60 0.61 0.62 0.59 0.62 b,d,f,h,j 
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a)  HIP FRACTURE                                                            b) HIP FRACTURE 
 
 
 
 
 
 
 
 
 
 
 
 
c) HIP FRACTURE                                               d) SPINE FRACTURE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6.1. Receiver Operating Characteristic (ROC) curves comparisons of hip and 
spine fractures 
P=0.26 P<0.01 
P<0.01 P=0.01 
Areal FN BMD (0.76) 
Cortical FN BMD (0.69) 
Areal FN BMD (0.76) 
Trabecular FN BMD (0.72) 
Trabecular FN BMD (0.72) 
Cortical FN BMD (0.69) 
Trabecular spine BMD (0.79) 
Areal spine (0.72)                 
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4.1 ABSTRACT 
Studies examining the relationship between muscle variables and bone strength have been 
previously published. However, none have included all three muscle measurements and/or both 
central and peripheral parameters. The purpose of this study was to explore the relationship 
between lean mass, strength, and power, and skeletal size, density and strength. We studied the 
association between appendicular lean mass (ALM), grip strength and leg power, and peripheral 
and central quantitative computed tomography parameters in 3,245 men aged 65 or older. ALM, 
grip strength, and leg power were measured by dual-energy X-ray absorptiometry (DXA), Jamar 
dynamometer, and the Nottingham Power Rig, respectively. Data was presented as least squares 
means generated from linear regression models. A multivariable model adjusting for potential 
confounders including age, race, study site, BMI, and muscle measurements were developed. For 
the multivariable model, percent differences between the lowest and highest quartiles (Q) were 
reported. ALM was associated with central and peripheral QCT parameters with statistically 
significant percent higher values (Q4 vs Q1) ranging from 2.8% (cortical vBMD) to 36.8% 
(Medullary volume). Grip strength was only associated with radial parameters with statistically 
significant percent higher values (Q4 vs Q1) ranging from 2.5% (periosteal circumference) to 
9.0% (Polar moment of inertia). There was no association between leg power, and central and 
peripheral QCT parameters. In older men, ALM was positively associated with central and 
peripheral QCT parameters. Higher grip strength was associated with higher radial strength and 
geometric parameters that have been previously related to non-spine fractures. Longitudinal 
studies are needed to further establish whether changes in lean mass, strength and power 
influence skeletal size, density and strength.  
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4.2 INTRODUCTION 
Muscles and bones are neighboring tissues with close ties and are both derived from a common 
mesenchymal precursor [2]. Throughout life, the loss of muscle mass and bone mass has been 
shown to be coupled and has been hypothesized to be part of the same functional unit [182]. The 
association of muscle mass or strength with DXA measures of areal BMD is well established 
[214] [215] [213] [212] [211] [216]. Since many non-osteoporotic individuals experience 
fractures, it is thought that bone geometry not captured by DXA may also play a role in fracture 
risk [249] [250]. Because of its proximity to bone, skeletal muscle force generates bending 
moments on bone potentially affecting its geometry [251]. Peripheral and central QCT measures 
of bone geometry have been associated with fracture risk [52] [247] [45].  Therefore, identifying 
the risk factors affecting bone geometric parameters such as the size and shape of the trabecular 
and cortical bone compartments may identify potential targets for interventions to reduce 
fractures.  
Few studies have examined the association between skeletal muscle mass, muscle 
strength and power, and bone geometry and strength properties. Available literature is limited to 
one or two muscle measurements, to specific skeletal sites, to younger individuals, to women 
only, or to a single technology [217, 218, 252, 253].  Of importance, these studies adjusted for 
potential confounders but not for other muscle mass measurements in their analyses. 
In this paper, the purpose was to study the association between muscle mass, strength and 
power, and measures of skeletal size, density, and strength.  
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4.3 MATERIALS AND METHODS 
The Osteoporotic Fractures in Men (MrOS) study is a multicenter prospective cohort study 
designed to identify risk factors for osteoporosis and osteoporotic fracture. This study consists of 
5,994 older men recruited from six sites (Birmingham, AL; Minneapolis, MN; Palo Alto, CA; 
Pittsburgh, PA; Portland, OR; and San Diego, CA) across the United States from March 2000 to 
April 2002 [157] [233]. To be eligible, men needed to be age 65 years or older, be able to walk 
without assistance from another person, and have reported no bilateral hip replacement. Human 
subjects’ approval was obtained at all sites with written informed consent obtained from all 
participants.   
 
Central QCT analytical cohort  
Due to limitations on study resources, the first 650 men and all nonwhite men enrolled at 
each clinical site were referred for QCT scans of the hip and lumbar spine as part of their 
baseline visit for a total of 3786 men (63% of the MrOS cohort). Out of these participants, 134 
failed because of insufficient number of images, interference from metal, calibration standard not 
visible, or unrecorded cause. From the remaining participants, 3,245 had complete whole body 
DXA and volumetric BMD measurements. Except for a higher proportion of minorities (12.9% 
vs 10.5%), the characteristics of men in the vBMD subset were similar to the overall sample of 
men in the cohort. The pelvic region from the femoral head to 3.5 cm below the lesser trochanter 
was scanned at settings of 80 kVp, 280 mA, 3-mm slice thickness, and 512 x 512 matrix in spiral 
reconstruction mode. Calibration standards containing known hydroxyapatite concentrations 
were included with the participant in every scan. 
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At the femoral neck, the following measures were obtained. The cross-sectional area 
(cm2) was computed as the area within the periosteal boundary at the minimum cross-section. 
Integral volume (cm3) was computed as the total volume of the ROI within the periosteal 
boundary. A trabecular volume was obtained by applying an erosion process to the integral 
volume to retain the same shape in a region fully contained within the medullary space. The 
cortical volume was defined by applying a threshold of 0.35 g/cm3 to all voxels between the 
periosteal boundary and the outer of the trabecular volume. Medullary volume was computed by 
subtracting the cortical volume from the integral volume. The percent cortical volume was 
computed as cortical volume divided by integral volume times 100%. vBMD (g/cm3) was 
computed as the concentration of calcium hydroxyapatite averaged over all voxels in the integral, 
trabecular, or cortical volumes. The spine parameters consisted of the total vertebral vBMD, 
cross sectional area, integral bone BMD, vertebral strength index L1-L2, and areal spine. 
 
pQCT analytical cohort  
 Men who returned for their second exam an average of 4.7±0.3 years later (from March 
2005 to May 2006) were invited to participate in an ancillary study involving pQCT at the 
Minneapolis and Pittsburgh clinical centers. Of the 1550 men who attended the second exam at 
the Pittsburgh and Minneapolis sites, 1171 (76%) completed the clinic visit and agreed to 
participate in a pQCT ancillary study and are included in the current analysis. A total of 657 men 
were deceased or terminated before being contacted for the second visit, and less than 1% 
declined to participate. This resulted in a return rate of 98% for the follow up visit. After 
excluding 8 men with missing or invalid information and 23 nonwhite men, this analysis 
53 
included 1143 subjects. Additionally, 58 participants were not included because whole body 
DXA was missing.   
The pQCT parameters that we selected for this analysis were previously shown to be 
associated with non-spine fractures [45]. As previously described, slices were obtained (2.3 ± 0.2 
mm) at the 4% and 66% sites of the left tibia and at 4% and 33% of the non-dominant forearm 
(radius). Slices are taken as a percentage of limb length from the distal end of the relevant bone. 
The XCT 2000 device (Stratec Inc., Pforzheim, Germany) and the XCT-3000 (Stratec Inc., 
Pforzheim, Germany) were used to obtain the scans in Pittsburgh and Minneapolis respectively. 
The difference between the scanners is the granty size. The same acquisition and analysis 
software (version 5.5) was used to analyze scans at both sites. We performed a precision study 
using a European forearm phantom scanned 3 times at each site at 200, 100, and 50 mg/cc 
respectively. Values on the two instruments were similar and within <0.5% for total area at all 
mg/cc, and from 0.5% to 1.0% for total density. Voxel size was 0.5 mm and the scan speed was 
25 mm/s. The anatomic reference line (distal edge of the tibial plafond and proximal point of the 
distal radial joint surface) was determined by acquisition of a 30-mm planar scout view of the 
joint line. Data were analyzed according to the manufacturer specifications. At the trabecular 4% 
sites, Contour mode 2 (169 mg/cm3) and Peel mode 1 (45% area) were used. At the more 
cortical 33% radius and 66% tibia sites, we used Contour mode 2 (169 mg/cm3) for cortical bone 
properties. A threshold of 280 mg/cm3 was used to determine the polar strength strain index 
(SSIp). Polar strength strain index (SSIp, mm3) and section modulus (mm3) were calculated as 
estimates of bone bending strength. SSIp is a density weighted section modulus value while 
section modulus includes only geometric properties. For the Minneapolis site, precision with 
repositioning was determined in adults (women n=11, men n=4, age 28.5 ± 6.5 years) as a 
54 
coefficient of variation (CV, %) and varied from 0.28 (TotBMD) to 1.20 (TrabArea) at the distal 
tibia and from 0.31 (CortBMD) to 0.41 (TotArea) at the shaft (cousins ref). Similar precision 
values were reported at the Pittsburgh site. An anthropomorphic phantom was scanned daily for 
quality assurance at both sites. 
We included parameters that estimate the resistance of bone to bending and torsional 
force as a result of inertial properties of mass distributed around the torsional or bending axis 
(cross sectional moment of inertia-CSMI) [254], the bone strength in bending and torsion based 
on distribution of density-weighted bone voxels from polar axis (polar strength index-SSIp, axial 
strength index- SSIx) [255], the ratio of the bone’s resistance to bending and torsion to its 
maximally distributed distance about the bending or torsional axis (section modulus-SM) [256], 
and the ability of the bone to resist torsion (polar moment of inertia-PMI) [45].  The participants 
provided informed consent, and the study was approved by the institutional review board at each 
site. 
 
Skeletal Muscle mass, strength and power measurements 
Lean mass of the extremities and total body fat was obtained using the Hologic QDR 
4500. Appendicular lean mass was calculated as the sum of lean mass in the arms and legs. Bone 
mineral content was removed from the lean mass calculation.  Grip strength (kg) was measured 
twice using a Jamar dynamometer (Jackson, MI, USA) in both the right and left arms [257]. The 
maximum grip strength from all tries was used in our analysis. The Nottingham Power Rig was 
used to measure leg power extension in watts. [258, 259]. All clinic staff performing DXA, leg 
power and grip strength measures completed formal, centralized training and passed a 
certification test.  
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Other Measurements 
Participants completed a questionnaire that collected information on demographics. Body 
weight was measured on balance beam scales (except for one site which used a digital scale). 
Height was measured on a Harpender stadiometer (DyFed, UK). Body mass index (BMI) was 
calculated as weight in kilograms divided by the square of height in meters. Physical activity was 
assessed with the Physical Activity Scale for the Elderly (PASE) with higher scores indicating a 
greater level of activity[260]. Information on previous fractures was obtained.  
 
Statistical analysis 
Baseline characteristics were compared across the groups using ANOVA for continuous 
variables and Chi Square for categorical ones. Pairwise comparisons of the baseline 
characteristics were calculated and p-values were included in Table 1. Central and peripheral 
QCT parameters were compared across quartiles of lean mass, strength and power quartiles.  
Multiple regression analysis was used to determine the association between quartiles of ALM, 
grip strength, leg power with measures of bone strength, geometry and volumetric density. All 
analyses were initially adjusted for age, study site, and race. The multivariable model included 
age, study site, race, BMI. Also, ALM, grip strength, and/or leg power were added to the MV 
model after testing for collinearity (variance inflation factor <5). Results were presented as least 
squares (LS) means. A trend test and pairwise comparisons were performed to compare the LS 
means of the QCT parameters. Statistical significance was set at p<0.05. For the multivariate 
model, percent differences between the lowest and highest quartiles (Q4 vs Q1) were reported. 
All statistical analyses were conducted using SAS version 9.3 (SAS Institute, Cary, NC, USA).  
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4.4 RESULTS 
Baseline characteristics 
Men with higher ALM, grip strength, and leg power were younger and more physically 
active. They also had higher BMI and total body fat.  A greater percentage of men with high 
ALM and muscle power had a history of fractures. Men with high appendicular lean mass also 
had a strong grip strength and leg power (Table 1). 
 
Bone outcomes 
Femoral neck – Statistically significant differences in all QCT parameters were observed 
across ALM quartiles. In the multivariable model, percent differences (Q4 vs Q1) for statistically 
significant QCT parameters between the lowest and highest ALM quartiles ranged between 2.8% 
(cortical vBMD) and 27.4% (Medullary volume). Most QCT parameters were statistically 
different across grip strength and muscle power quartiles (Table 2). In the multivariable model, 
however, these associations lost their statistical significance. Areal FN BMD was positively 
associated with both ALM and grip strength (Figure 1).   
Spine - Statistically significant differences in all spine QCT parameters were observed 
across ALM quartiles (Table3). In the multivariate model, percent differences for statistically 
significant QCT parameters between the lowest and highest ALM quartiles ranged between 3.1% 
(integral vBMD) and 21.9% (vertebral strength). Grip strength and leg power were associated 
with CSA and integral bone vBMD in the initial model. For grip strength, no association was 
seen after adjusting for additional confounders.  However for leg power, there was a 3.3% and 
11.5% interquartile decrease in CSA and vertebral strength respectively. After adjusting for 
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ALM and grip strength, areal FN BMD was positively associated with both ALM and grip 
strength (Figure 2).  
Radius - Statistically significant differences in tibia QCT parameters were observed 
across ALM, grip strength, and muscle power quartiles (Table 3). In the multivariable model, 
percent differences for statistically significant pQCT parameters between the lowest and highest 
quartiles ranged between 9.2% (periosteal circumference) and 36.8% (PMI) for ALM, between 
2.5% (periosteal circumference) and 9.0% (PMI) for grip strength. There was no association 
between leg power and radius pQCT parameters (Figure 3). 
Tibia - Statistically significant differences in tibia QCT parameters were observed across 
ALM, grip strength, and muscle power quartiles (Table 4). In the multivariable model, percent 
differences for statistically significant pQCT parameters between the lowest and highest quartiles 
ranged between 15.6% (33% cortical BMC) and 35.6% (33% PMI) for ALM. There was no 
association between grip strength and leg power, and tibia pQCT parameters (Figure 4). 
4.5 DISCUSSION 
Findings of this analysis showed that ALM was positively associated with central and peripheral 
QCT parameters. These associations were independent of grip strength and muscle power. The 
relationship between ALM and all QCT parameters was stronger compared to that of grip 
strength and leg power. This positive association remained robust even after adjusting for the 
other muscle measurements. This suggests that the mechanical load of the lean mass on bone 
may contribute more to their size, density and strength than the muscle strength and power. At 
the femoral neck, ALM was associated with bone size parameters including CSA, medullary, 
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cortical and integral volumes. Cortical vBMD was the only density measurement related to 
ALM. No associations were observed between ALM, and trabecular and integral vBMD. In 
previous studies, the structural and biomechanical bone strength of the proximal femur has been 
associated with hip fracture risk independently of BMD [52] [261]. Specifically, Black et al. 
demonstrated that one SD decrease in cortical vBMD and volume was related to a higher risk of 
hip fracture independent of aBMD. FN trabecular vBMD did not however improve hip fracture 
prediction compared to FN areal BMD [52]. At the spine, we showed that the ALM interquartile 
percent differences were the highest for CSA and vertebral strength. This is an important finding 
since in older men, vertebral strength has been shown to be highly related to vertebral fracture 
risk in comparison to areal BMD [247]. Peripherally, ALM was associated with the bone 
strength and geometry of the radius and tibia. Although the MrOS study doesn’t include 
microarchitecture measures of bones, it is important to note that ALM is related to the trabecular 
number and spacing of the radius. Furthermore, in another paper, the STRAMBO study research 
team found that muscle mass was associated with bone size of the forearm [218]. 
Grip strength was related only to areal BMD measurements centrally. Similar to our 
findings, low grip strength has been previously found to be associated with areal BMD at the 
spine and femoral neck [262]. However, despite its association with vertebral fractures, our 
results showed no relationship between grip strength and the size, volumetric BMD, and strength 
of the hip and spine. Furthermore, we found an association between grip strength and the 
geometry and strength parameters at the radius, but not at the tibia suggesting site specific 
effects. Concordantly, Kaji et al. demonstrated that grip strength is correlated with the vBMD, 
cortical area, cortical thickness, and polar strength strain index of the forearm. [263]. The 
STRAMBO study also showed that low grip strength was associated with poor cortical and 
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trabecular microarchitecture but not with the CSA of the radius in older men [218]. This 
reiterates the importance of the integrated nature of skeletal muscle and bone. The stronger 
associations found between grip and radius structural and geometric parameters may be 
explained by the muscle attachments on the bones. Muscles of the forearm such as the flexors 
originate from the epicondyle of the humerus (proximal to radius) and inserts on the wrist (distal 
to radius). Since grip strength is used to measure muscle strength, a high correlation with radius 
parameters is expected. We postulated that this may be why greater percent differences in radius 
parameters were observed between the lowest and highest grip strength quartiles. This is not the 
case for the hip, spine, and tibia. For instance, very few muscles cross the femoral neck with 
most muscles attaching more distally on the trochanter of the femur. Therefore, during muscle 
contractions skeletal muscles exert minimal strain on the neck of the femur. 
Negative associations were seen between leg power and spine parameters (CSA and 
vertebral strength) after adjusting for BMI, ALM and grip strength. No association was found 
between leg power and peripheral QCT parameters. These results are contradictory with a 
previous study we conducted using the same MrOS cohort. In that study, we examined the 
relationship between muscle power and pQCT parameters and found an association between leg 
power and bone strength parameters (cross sectional area and the polar strength strain index) 
[252]. However, the multivariable model did not include lean mass and grip strength. Despite the 
fact that leg power explains 6.6% of the variance in bone-strength strain index and 8.9% of the 
variance in the section modulus (SM) at the tibial mid-shaft, we did not find any association 
between leg power and tibial strength parameters [253]. Furthermore, the previous variances 
were obtained from a study conducted in women, which may suggest some gender differences in 
the muscle power association with tibial bone parameters.   
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There are several strengths to our study.  MrOS is a multicenter prospective study 
examining potential risk factors for fractures in a large population of older men. We were able to 
examine the association of lean mass, grip strength and leg power with central and peripheral 
QCT parameters.  There are also several limitations to our study. Peripheral QCT measurements 
were available for a smaller number of MrOS men, and the peripheral and central parameters 
cohorts were not the same. Another limitation is that the Nottingham power rig is limited as a 
measure of power because it does not separate velocity from force. Also, since this is a cross 
sectional study, we were unable to establish a temporal relationship between the muscle 
measurements and QCT parameters. 
In older men, the ALM was positively associated with central and peripheral QCT 
parameters. The ALM and grip strength were associated with peripheral strength and geometric 
parameters that have been previously related to non-spine fractures [45]. Additionally, the 
stronger relationship observed for ALM suggests that the mechanical load of the muscles on 
bones may contribute more to their size, density and strength compared to the muscle strength 
and power. Future efforts to increase muscle size may play a key role in improving density and 
quality of bones. Longitudinal studies are needed to further establish whether changes in ALM 
and strength improves the skeletal size, density, and strength. 
61 
4.6 TABLES AND FIGURES 
Table 4.6.1. Baseline characteristics across appendicular lean mass, grip strength, and muscle power quartiles 
 Characteristics Q1 Q2 Q3 Q4 p-trend 
 
 
 
 
 
Appendicular 
lean mass 
Age 76.41 ±6.41 73.97 ±5.56 72.50 ±5.28 71.02 ±4.71 <0.0001 
Caucasian 668(84.03) 724(91.18) 727(91.68) 699(87.92) <0.0001 
Height (m) 
Weight (kg) 
BMI (kg/m2) 
1.69 ±0.06 
69.86 ±7.41 
24.57 ±2.62 
1.73 ±0.05 
78.76 ±7.50 
26.40 ±2.76 
1.75 ±0.06 
86.03±8.00 
28.05 ±3.15 
1.79 ±0.06 
96.11 ±11.17 
30.06 ±3.88 
<0.0001 
<0.0001 
<0.0001 
Total body fat (kg) 17.66 ±5.20 20.19 ±5.92 22.80 ±6.51 25.17 ±7.59 <0.0001 
PASE score 139.33±67.73 147.13 ±66.19 153.33 ±66.38 153.57 ±67.37 <0.0001 
Nottingham leg power (N) 163.29±45.26 197.01±49.45 218.95±54.52 249.88±66.50 <0.0001 
Appendicular lean mass (kg) 20.03 ±1.40 23.00±0.62 25.11±0.64 28.79 ±2.22 <0.0001 
Grip strength (kg) 36.41 ±6.88 40.78±7.21 43.26 ±7.29 46.91±8.77 <0.0001 
Previous fracture (N, %) 394(49.56) 433(54.60) 438(55.23) 456(57.36) 0.015 
 
 
 
Grip strength 
Age 77.03±6.45 74.37 ±5.47 72.64±5.25 70.47 ±4.39 <0.0001 
Caucasian 
Height 
Weight 
572(87.86) 
1.70 ±0.07 
78.11 ±12.63 
745(88.27) 
1.73 ±0.06 
81.02 ±12.79 
722(88.92) 
1.74 ±0.06 
83.26 ±12.59 
740(89.81) 
1.78 ±0.06 
87.67 ±12.05 
0.65 
<0.0001 
<0.0001 
BMI 26.86±3.76 27.10 ±3.86 27.33 ±3.80 27.75±3.49 <0.0001 
Total body fat 20.80 ±6.64 21.38 ±6.93 21.50 ±7.17 22.06 ±6.95 0.007 
PASE score 131.63±64.05 143.37 ±64.39 152.33±70.54 162.33 ±66.71 <0.0001 
Nottingham leg power 162.72±52.51 188.92 ±50.08 214.26 ±55.35 251.83 ±58.64 <0.0001 
Appendicular lean mass 
Grip strength 
22.24 ±3.33 
30.36 ±3.92 
23.40 ±3.12 
38.23 ±1.65 
24.53 ±2.99 
43.86 ±1.64 
26.38 ±3.16 
52.57 ±4.32 
<0.0001 
<0.0001 
Previous fracture 363(55.76) 456(54.03) 441(54.38) 436(52.91) 0.75 
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Muscle Power 
Age 77.44±6.03 74.25±5.45 71.96±4.75 69.85±3.93 <0.0001 
Caucasian 
Height 
Weight 
639(87.90) 
1.71 ±0.07 
76.55±11.55 
642(88.07) 
1.73 ±0.06 
80.16±12.24 
647(89.00) 
1.75 ±0.06 
83.41±11.67 
655(89.73) 
1.77 ±0.06 
89.73±11.92 
0.66 
<0.0001 
<0.0001 
BMI 26.13±3.57 26.78±3.63 27.19±3.50 28.58±3.53 <0.0001 
Total body fat 19.86±6.49 20.81±6.97 21.28±6.79 23.13±6.83 <0.0001 
PASE score 129.63±65.73 147.16±64.31 158.69±66.90 161.50±67.76 <0.0001 
Nottingham leg power 130.51±25.55 183.67±11.65 224.96±11.31 288.89±38.66 <0.0001 
Appendicular lean mass 
Grip strength 
22.06±3.10 
36.19±7.21 
23.34±2.85 
40.27±7.06 
24.66±2.88 
43.83±7.16 
26.76±3.13 
47.72±7.82 
<0.0001 
<0.0001 
Previous fracture 360(49.52) 391(53.64) 413(56.81) 412(56.44) 0.019 
Table 4.6.1. Continued 
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Table 4.6.2. Quartiles of appendicular lean mass, grips strength, and muscle power by central QCT parameters:  
Age, race and site adjusted 
 Characteristics Q1 Q2 Q3 Q4 p-trend Pairwise 
 
 
 
Appendicular 
lean mass 
Femoral neck       
Cross-sectional area (cm2) 11.44 12.09 12.50 13.19 <0.0001 abcdef 
Percent cortical volume 45.12 45.25 46.07 45.74 0.016 bd 
Integral vBMD (g/cm3) 0.290 0.294 0.303 0.305 <0.0001 bcde 
Cortical volume (cm3) 8.03 8.65 9.28 10.06 <0.0001 abcdef 
Integral volume (cm3) 17.90 19.30 20.41 22.29 <0.0001 abcdef 
Medullary volume (cm3) 9.88 10.65 11.14 12.23 <0.0001 abcdef 
Cortical vBMD (g/cm3) 0.517 0.522 0.530 0.537 <0.0001 bcdef 
Trabecular vBMD (g/cm3) 0.076 0.079 0.085 0.086 <0.0001 bcde 
Femoral neck BMD (g/cm2) 0.753 0.786 0.824 0.854 <0.0001 abcdef 
Spine       
Total vertebral vBMD (g/cm3) 0.116 0.118 0.121 0.125 <0.0001 bcef 
Cross sectional area (cm2) 10.89 11.62 11.98 12.76 <0.0001 abcdef 
Integral bone BMD (g/cm3) 0.210 0.215 0.221 0.228 <0.0001 abcdef 
Areal spine (g/cm2) 1.01 1.05 1.08 1.13 <0.0001 abcdef 
Vertebral strength index L1-L2 (N) 0.261 0.287 0.313 0.353 <0.0001 abcdef 
 
 
 
 
Grip strength 
Femoral neck       
Cross-sectional area (cm2) 11.75 12.04 12.38 12.79 <0.0001 abcdef 
Percent cortical volume 45.52 45.63 45.41 45.69 0.819  
Integral vBMD (g/cm3) 0.296 0.296 0.296 0.301 0.219  
Cortical volume (cm3) 8.557 8.741 8.989 9.422 <0.0001 bcdef 
Integral volume (cm3) 18.91 19.35 20.00 20.87 <0.0001 bcdef 
Medullary volume (cm3) 10.36 10.61 11.01 11.45 <0.0001 bcdef 
Cortical vBMD (g/cm3) 0.523 0.524 0.524 0.529 0.160  
Trabecular vBMD (g/cm3) 0.079 0.079 0.082 0.086 0.002 cef 
Femoral neck BMD (g/cm2) 0.784 0.789 0.803 0.826 <0.0001 bcdef 
Spine       
Total vertebral vBMD (g/cm3) 0.118 0.119 0.120 0.121 0.455  
Cross sectional area (cm2) 11.43 11.54 11.84 12.11 <0.0001 bcdef 
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a: Q1 vs Q2, b: Q1 vs Q3, c: Q1 vs Q4, d: Q2 vs Q3, e: Q2 vs Q4, f: Q3 vs Q4 
 
 
 
 
 
 
 
Integral bone BMD (g/cm3) 0.216 0.216 0.217 0.222 0.015 cef 
Areal spine (g/cm2) 1.040 1.046 1.066 1.091 <0.0001 bcdef 
Vertebral strength index L1-L2 (N) 0.297 0.290 0.299 0.315 0.069 e 
 
 
 
Muscle 
Power 
Femoral neck       
Cross-sectional area (cm2) 11.76 12.13 12.44 12.78 <0.0001 abcdef 
Percent cortical volume 45.42 45.35 45.81 45.92 0.320  
Integral vBMD (g/cm3) 0.294 0.294 0.301 0.302 0.016 bcde 
Cortical volume (cm3) 8.460 8.794 9.100 9.609 <0.0001 abcdef 
Integral volume (cm3) 18.82 19.56 20.09 21.16 <0.0001 abcdef 
Medullary volume (cm3) 10.36 10.76 11.00 11.55 <0.0001 abcef 
Cortical vBMD (g/cm3) 0.520 0.522 0.528 0.528 0.037 bc 
Trabecular vBMD (g/cm3) 0.079 0.079 0.083 0.086 0.0054 bce 
Femoral neck BMD (g/cm2) 0.776 0.790 0.811 0.831 <0.0001 abcdef 
Spine       
Total vertebral vBMD (g/cm3) 0.118 0.118 0.120 0.123 0.063 ce 
Cross sectional area (cm2) 11.45 11.62 11.77 12.03 <0.0001 bcef 
Integral bone BMD (g/cm3) 0.214 0.214 0.219 0.223 0.0002 bcde 
Areal spine (g/cm2) 1.041 1.051 1.068 1.086 0.0004 bce 
Vertebral strength index L1-L2 (N) 0.293 0.287 0.300 0.311 0.118 e 
Table 4.6.2. Continued 
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Table 4.6.3. Quartiles of appendicular lean mass, grips strength, and muscle power by peripheral QCT parameters:  
Age, race, and site adjusted 
 
All p trends were statistically significant 
 
 
Characteristics Appendicular lean mass Grip Strength Muscle power 
 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 
FN aBMD 0.73 0.77 0.79 0.82 0.78 0.76 0.77 0.79 0.78 0.79 0.80 0.81 
Tibia 4% 
Total BMC (mg/mm) 
Trabecular BMC (mg/mm) 
SSIx (mm3) 
SSIp (mm3) 
 
338.1 
113.3 
1125.6 
2109.5 
 
370.1 
126.5 
1300.5 
2419.5 
 
380.8 
128.3 
1337.7 
2528.0 
 
405.6 
138.1 
1467.3 
2755.1 
 
360.6 
121.6 
1257.6 
2350.7 
 
361.7 
121.1 
1250.2 
2331.6 
 
370.4 
125.0 
1295.0 
2408.1 
 
390.1 
132.3 
1378.2 
2600.6 
 
366.0 
122.8 
1286.2 
2406.0 
 
375.7 
127.6 
1313.7 
2470.4 
 
381.4 
128.3 
1350.1 
2549.0 
 
402.2 
136.7 
1443.1 
2719.2 
Radius 33% 
Total BMC (mg/mm) 
Total CSA (mm2) 
Cortical BMC (mg/mm) 
Cortical CSA (mm2) 
Periosteal circumference (mm) 
CSMI (mm4) 
PMI (mm4) 
SM (mm3) 
SSIx (mm3) 
SSIp (mm3) 
 
121.3 
132.5 
112.8 
96.28 
40.72 
1094.7 
2536.6 
307.6 
180.6 
317.01 
 
130.3 
140.9 
122.3 
104.47 
42.01 
1262.5 
2948.7 
340.8 
200.9 
348.5 
 
136.4 
147.5 
127.6 
109.29 
42.98 
1369.7 
3204.4 
361.7 
213.3 
369.8 
 
144.0 
158.3 
134.5 
115.56 
44.52 
1549.0 
3665.7 
398.1 
232.0 
404.6 
 
125.3 
137.3 
116.5 
100.2 
41.43 
1194.9 
2774.0 
324.7 
190.2 
332.0 
 
130.0 
142.9 
121.0 
103.6 
42.27 
1265.5 
2953.9 
340.1 
200.9 
347.5 
 
133.1 
143.9 
124.8 
106.5 
42.43 
1322.1 
3079.7 
351.9 
207.2 
361.4 
 
141.4 
153.4 
132.5 
113.2 
43.82 
1472.4 
3466.8 
383.8 
223.9 
392.1 
 
128.8 
139.1 
120.4 
103.0 
41.70 
1237.0 
2867.4 
335.8 
195.3 
342.2 
 
131.8 
142.8 
123.2 
105.4 
42.26 
1283.3 
3024.1 
346.0 
202.4 
353.2 
 
134.9 
145.0 
126.4 
107.9 
42.60 
1347.7 
3129.8 
357.2 
210.6 
364.4 
 
140.0 
151.4 
131.3 
112.5 
43.52 
1447.2 
3412.7 
379.2 
220.2 
384.6 
Tibia 33% 
Cortical BMC (mg/mm) 
PMI (mm4) 
SSIx (mm3) 
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Figure 4.6.1. Percent difference in means of femoral neck parameters between 1st and 4th quartiles of ALM, grip strength, and 
leg powera 
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Figure 4.6.2. Percent difference in means of spine parameters between 1st and 4th quartiles of ALM, grip strength, and leg powera 
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*Statistically significant with p<0.05 
a MV model site, age, race, BMI, grip strength and leg power (for ALM), ALM and leg power (for grip strength), and ALM and grip strength 
(for leg power). 
 
Figure 4.6.3. Percent difference in means of radius QCT parameters between 1st and 4th quartiles of ALM, grip strength, and  
leg powera
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*Statistically significant with p<0.05 
a MV model site, age, race, BMI, grip strength and leg power (for ALM), ALM and leg power (for grip strength), and ALM and grip strength 
(for leg power). 
 
Figure 4.6.4. Percent difference in means of Tibia QCT parameters between 1st and 4th quartiles of ALM, grip strength, and leg 
powera
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5.1 ABSTRACT 
The combined effect of age-related deterioration in bone and muscle manifested as low bone 
mineral density (BMD) and sarcopenia on fracture risk has not been reported. We examined 
whether men and women with both low BMD and sarcopenia have a higher risk of fracture than 
those with only one or neither condition. 5,544 men (mean age=73.7 years) from the 
Osteoporotic Fractures in Men study and 1,114 women (mean age=77.6 years) from the Study of 
Osteoporotic Fractures were followed up for 9 years and 8 years respectively. Sarcopenia was 
defined as low appendicular lean mass plus either slowness or weakness; and low BMD 
according to the World Health Organization definition of T-score<-1.0. Participants were 
classified as normal BMD and no sarcopenia (N=3367 men, 308 women); sarcopenic only 
(N=79 men; 48 women); low BMD only (N=1986 men; 626 women), and low BMD and 
sarcopenic (N= 112 men; 132 women). Men had 870 confirmed radiographic non-spine 
fractures, and women 272. Cox Proportionate Hazards Models were used to assess fracture risk. 
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Compared to men with normal BMD and no sarcopenia, the Hazard ratio [HR] for fracture was 
3.79 (95% confidence interval [CI], 2.65-5.41) among men with low BMD and sarcopenia, 1.67 
(95% CI: 1.45-1.93) among men with low BMD only, and 1.14 (95% CI, 0.62-2.09) among men 
with sarcopenia only (p-interaction=0.06). Women with low BMD and sarcopenia (HR, 2.27; 
95% CI, 1.37-3.76), and women with low BMD alone (HR, 2.62; 95% CI, 1.74-3.95), but not 
women with only sarcopenia had increased risk of fracture compared to normal women. Our data 
indicate that men with both low BMD and sarcopenia are at especially high risk of fracture. 
Efforts to identify men with low BMD and sarcopenia may help prevent future fractures. 
5.2 INTRODUCTION 
Age-related deterioration in both bone and muscle manifested as low bone mineral density 
(BMD) and sarcopenia may contribute to fractures. It is well established that individuals with 
low BMD have an increased risk of fracture [76].  
Falls and functional impairments, which are known to be associated with fractures, have 
been previously linked to sarcopenia[264] [167]. Furthermore, myosteatosis, which results in 
reduced muscle strength and function, has been associated with fractures [265] [266]. Hence, 
sarcopenia may increase risk of fractures. 
Sarcopenia was initially defined as the loss of muscle mass [104]. However, more recent 
definitions of sarcopenia add components of muscle strength and/or physical performance, 
because the loss of muscle mass is not sufficient to characterize the sarcopenic syndrome [115]. 
Inclusion of these additional measures in the operational definition of sarcopenia may improve 
the prediction of clinical outcomes, such as fractures.  
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In 2009, the term “sarco-osteopenia” was coined to emphasize that both weak bones and 
weak muscles may contribute to fractures in the elderly [267].  To our knowledge, the combined 
effect of both sarcopenia, defined as low muscle mass and strength, and low BMD on fracture 
risk has not yet been studied. 
The purpose of the current study was to compare the incidence of non-vertebral fractures 
among men and women based on both low BMD and sarcopenia. We hypothesized that 
individuals with both sarcopenia and low BMD will have the greatest risk of fracture compared 
to individuals with only one or neither condition. 
5.3 METHODS 
Study population 
We examined data of 5,544 white and black men (mean age=73.7years) from the 
Osteoporotic Fractures in Men (MrOS) study and 1,114 white and black women (mean age=77.6 
years) from the Study of Osteoporotic Fractures (SOF). The MrOS and SOF studies are both 
multicenter prospective cohort studies designed to identify risk factors for osteoporosis and 
osteoporotic fracture. In MrOS, 5994 older men were recruited from six sites (Birmingham, AL; 
Minneapolis, MN; Palo Alto, CA; Pittsburgh, PA; Portland, OR; and San Diego, CA) across the 
United States from March 2000 to April 2002[157, 233]. In SOF, 9,704 women were recruited 
from four US sites (Baltimore, MD; Minneapolis, MN; Pittsburgh, PA; Portland, OR) between 
1986-1988. The original SOF cohort was enhanced by the addition of 662 African American 
women recruited between 1997-98. To be eligible, both men and women needed to be age 65 
years or older, be able to walk without assistance from another person, and have reported no 
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bilateral hip replacement. Human subjects approval was obtained at all sites with written 
informed consent obtained from all participants. 
Body composition by whole body Dual Energy X-ray Absorptiometry (DXA) was 
available for the 5,544 white and black MrOS men at baseline and a subset of 1,114 white and 
black SOF women (when recruited for the year 10 exam). Women without whole body DXA 
were not included since sarcopenia cannot be assessed without appendicular lean mass. 
 
Bone Mineral Density (BMD) measurement 
In men, total hip BMD (g/cm2) and femoral neck BMD (g/cm2) were measured using 
DXA Hologic QDR 4500(Bedford, MA). In women, BMD was measured by DXA using 
Hologic 1000 and 2000 scanners. Details of the measurement and densitometry procedures have 
been published elsewhere [234] [231]. Briefly, certified technicians performed the DXA scans 
following a strict protocol. To assess longitudinal performance of the scanners, an 
anthropometric spine phantom was scanned daily and a hip phantom weekly at each clinical 
center. In both genders, the right hip was scanned unless there was a fracture, implant, hardware, 
or other problem, in which case the left hip was scanned. Individuals were classified as having 
low BMD according to the 1994 World Health Organization (WHO) recommendations if their 
femoral neck T-score was < -1 [268]. Subjects were considered to have normal BMD if their T-
score was >= -1. The T-score was calculated using the National Health and Nutrition 
Examination Survey III reference database [28]. Young Caucasian women were used as the 
reference population in both men and women as recommended by the International Society for 
Clinical Densitometry (ISCD) [29].  
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Sarcopenia assessment 
The definition of sarcopenia was based on the European Working Group on Sarcopenia 
in Older persons (EWSOP) [115]. Participants were classified as sarcopenic if they had low lean 
mass plus either slowness (classified by gait speed) or weakness (assessed by grip strength). Low 
lean mass was defined using the approach of Newman et al [146] to correct appendicular lean 
mass for height and fat mass. Linear regression was used to model the relationship between 
appendicular lean mass on height (meters) and fat mass (kg). The 20th percentile of the 
distribution of residuals was used as the cutpoint for low muscle mass. Separate models were fit 
for men and women. We concentrated on the residual method because in the Health, Aging and 
Body Composition (Health ABC) and the Framingham studies, the residuals method was a better 
predictor of disability and mobility limitations in both men and women but other definitions of 
sarcopenia were not [123, 147].  Walking speed was calculated as the average two usual walking 
pace attempts over 6 meters and expressed as m/s. Slowness was defined as gait speed slower 
than 0.8 m/s. Grip strength was measured using a Jamar dynamometer (Jackson, MI, USA) in 
men and a handheld dynamometer (Sparks Instruments and Academics, Coralville, Iowa) in 
women. The maximum grip strength from all attempts was used in our analysis. Weakness was 
assessed by grip strength and characterized as less than 30 kg for men, or less than 20 kg for 
women. For each participant, height was measured on a Harpenden stadiometer (DyFed, UK). 
Lean mass of extremities and total body fat were obtained using the Hologic QDR 4500 and 
2000 for men and women, respectively. Appendicular lean mass was calculated as the sum of 
lean mass in the arms and legs. Bone mineral content was removed from the lean mass 
calculation.  
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Subjects’ classification 
Men and women were classified into four groups based on their bone mass and 
sarcopenia status: 1) Individuals with normal BMD and no sarcopenia (N=3367, 61% men; 308, 
28% women), 2) individuals with normal BMD and sarcopenia (N=79 men, 1% men; 48, 4% 
women), 3) individuals with low BMD and no sarcopenia (N=1986 men, 36% men; 626, 56% 
women), 4) and individuals with low BMD and sarcopenia (N= 112 men, 2% men; 132, 12% 
women).  
 
Other Measurements 
Covariates were assessed at baseline in men and at year 10 in women at the time of the 
whole body DXA. Participants completed questionnaires and interviews that collected 
information on demographics, lifestyle, medical history and a medication inventory. Participants 
were asked to bring all prescription and over-the-counter medications to the clinic for 
verification of use [269]. Smoking status was categorized as current or not (former, none) and 
alcohol consumption was assessed by the average number of drinks per week. Participants were 
asked if they walked as a form of exercise. Self-rated health was categorized as excellent/good vs 
fair, poor or very poor. Information on history of falls in the past year and previous fractures was 
obtained. Functional status was assessed by asking about difficulty with five instrumental 
activity of daily living (IADL) (“walking 2 or 3 blocks outside on level ground”, “climbing up 
10 steps without resting”, “preparing meals”, “doing heavy housework”, and “shopping for 
groceries or clothes”). Weight was measured on balance beam scales (except for one of the 
MrOS site which used a digital scale). Body mass index (BMI) was calculated as the weight in 
kilograms divided by the square of height in meters.  
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Fracture Ascertainment 
All non-spine fractures were identified through our mailed questionnaire follow-ups 
which were mailed every 4 months to ask if the participants had sustained a new fracture; these 
contacts were > 95% complete. Participants who reported a fracture were asked about the 
circumstances of the fracture.  The degree of trauma was categorized into: “fall from a standing 
height or less” ;“fall on stairs, steps or curb”, “fall from more than standing height”, and 
traumatic. Traumatic fractures (minimal, moderate, and severe) were included since they have 
been previously associated with low BMD [238]. Pathological fractures were excluded. All 
fractures were confirmed by radiographic report and adjudicated centrally over a mean of 9 years 
for men and 8 years for women. These analyses included fractures that occurred between 2000 
and 2012 in men, and between 1997 and 2009 in women. The follow-up time ended at the date of 
the first fracture, date of death, date of last contact or database lock. In sensitivity analyses, we 
excluded traumatic fractures (N=167, 19% in men; N=23, 8% in women). 
 
Statistical analysis 
Baseline characteristics were compared across the groups using ANOVA for continuous 
variables and Chi Square for categorical ones. Pairwise comparisons of the baseline 
characteristics were calculated and p-values were included in Table 1. 
For the primary outcome, we initially adjusted for age. The incidence rates of non-spine 
fractures for each of the four groups were estimated using a Poisson distribution. Using Cox 
Proportional Hazards Models, the age and multivariable adjusted Hazard ratios (HR) and 95% 
Confidence Intervals were calculated. Participants with normal BMD and no sarcopenia formed 
the referent group. The multivariable-adjusted model included established risk factors for 
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fracture: age, race, fall history, previous fracture history, current smoking, glucocorticoids, 
rheumatoid arthritis, alcohol consumption, IADL impairments, and physical activity. We used 
backward elimination to drop all variables that did not reach a statistically significant level of 
p<0.1. The interaction term between low BMD and sarcopenia on fracture risk was assessed. 
Sensitivity analyses were conducted for different sarcopenia operational definitions. We also 
studied the association between low BMD and fracture risk adjusting for sarcopenia, and the 
association between sarcopenia and fracture risk adjusting for low BMD. In participants who 
experienced a non-spine fracture, pairwise comparisons were done to compare the circumstances 
of the fracture across the four groups.  
Separate analyses were done for men and women using SAS 9.3 (SAS Institute, Inc., 
Cary, NC). 
 
5.4 RESULTS 
The majority of men were white with little difference in race across the groups. Sarcopenic men 
with or without low BMD were older than the other groups but there was little variability in 
smoking and alcohol consumption among the groups. A higher percentage of women with low 
BMD with or without sarcopenia were white and these women tended to be older. Total hip and 
femoral neck BMD were the lowest in the low BMD and sarcopenia group in men, and in the 
low BMD with or without sarcopenia groups in women. Unlike sarcopenic women, sarcopenic 
men had a higher number of IADL impairments, and a higher percentage of falls. 
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Men  
A total of 870 (16%) men experienced a non-spine fracture: 402 (12%) normal; 11 (14%) 
sarcopenic; 421 (21%) low BMD; and 36 (32%) both low BMD and sarcopenia. The age-
adjusted incidence of non-spine fracture was similar in normal men (13.2 per 1,000) and those 
with sarcopenia alone (15.1 per 1,000), but was much higher in men with both low BMD and 
sarcopenia (46.5 per 1,000) (Figure 1). Men with low BMD and sarcopenia had a 4-fold 
increased risk of fracture in comparison to normal men, HR= 3.75(2.64 to 5.32), Table 2. Men 
with sarcopenia alone did not have a statistically significant higher risk of fractures 
HR=1.19(0.65 to 2.17), however, the risk of fracture in those with low BMD alone 
HR=1.79(1.56 to 2.05) was intermediate between normal men and men with both conditions.  
These associations remained significant after adjusting for important covariates (Table 2). The 
interaction term between sarcopenia and low BMD was borderline significant (p=0.06). Low 
BMD was associated with fracture risk after adjusting for sarcopenia (HR, 1.97; 95% CI, 1.72-
2.25). Similarly, sarcopenia was associated with fracture risk after adjusting for low BMD (HR, 
2.25; 95% CI, 1.68-3.03). Exclusion of traumatic fractures showed somewhat similar results 
(Table 2b, p-interaction=0.11). 
 
Women 
Overall, 272 (25%) women experienced a non-spine fracture: 31 (10%) normal; 7 (15%) 
sarcopenic; 194 (33%) low BMD; and 40 (32%) both low BMD and sarcopenia. The age-
adjusted incidence of fracture ranged from 13.9 per 1,000 in normal women to about 40 per 
1,000 in women with low BMD or both low BMD and sarcopenia (Figure 1). Of interest, there 
was little gender difference in fracture incidence rates in subjects with low BMD and sarcopenia 
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(Figure 1).  Women with low BMD with or without sarcopenia had an approximately 3-fold 
increased risk of fracture compared to normal women, HR= 2.80(1.72 to 4.58) and 3.09 (2.08 to 
4.59) respectively (Table 2). The effect size decreased to 2.5 in both groups after adjusting for 
important covariates but remained statistically significant. Women with sarcopenia alone had a 
similar fracture rate as normal women. The interaction term between sarcopenia and low BMD 
was not statistically significant (p=0.37). Low BMD was associated with fracture risk after 
adjusting for sarcopenia (HR, 3.48; 95% CI, 2.47-4.90). However, sarcopenia was not associated 
with fracture risk after adjusting for low BMD (HR, 1.09; 95% CI, 0.79-1.49). Exclusion of 
traumatic fractures revealed similar results (Table 2b, p-interaction=0.38). 
 
Circumstances of the fracture  
Overall 80% of fractures in men and 90% in women involved a fall.  In men with both 
low BMD and sarcopenia, 75% of their non-spine fractures involved a fall from a standing height 
or less.  In comparison, fewer fractures in the other groups (between 56% and 64%) involved a 
fall from a standing height or less (Figure 2a.).  Pairwise comparisons showed that differences 
were statistically significant between men with both low BMD and sarcopenia and men with low 
BMD alone, and between men with both low BMD and sarcopenia and men without both 
conditions.  
Similarly, in women, a higher proportion of fractures in subjects with both low BMD and 
sarcopenia were due to a fall from < standing height (82%) compared to women with low BMD 
alone (75%), sarcopenia alone (67%), and normal women (78%). However, these differences 
were not statistically significant (Figure 2b). 
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5.5 DISCUSSION 
The findings of this study show that men with both low BMD and sarcopenia have a 4-fold 
higher risk for non-spine fractures compared to men with normal BMD and no sarcopenia. In 
men, the borderline significance of the interaction term suggests that the effect of sarcopenia and 
low BMD on fracture risk may depend on each other. The risk of fracture was about 2.5-fold 
higher in women with both sarcopenia and low BMD as well as in women with low BMD alone. 
Sarcopenia alone was not an independent risk factor for fractures in men and women.  Our 
findings illuminate a previously unrecognized and potentially strong role of sarcopenia in 
determining the risk of fractures among older men.  
The coexistence of low BMD and sarcopenia in older men resulted in a much higher risk 
of fractures. Since, physical activity, IADL impairments, history of falls, and other mobility 
disorder risk factors were adjusted for in our analyses, this suggests that the increased risk of 
non-spine fractures in men with both low BMD and sarcopenia could be attributed to the 
crosstalk between muscles and bones. Mechanical stimuli, pleiotropy, and hormones are known 
to play major roles in this crosstalk possibly affecting bone strength [3]. Indeed, circumstances of 
fractures showed that these men had a higher proportion of fractures due to a lower degree of 
trauma compared to men with low BMD alone and normal men. Low muscle mass and strength 
have been associated with low BMD[211] [212] [213] [214] [215] [216] and poorer quality of 
bones [217] [218] which may be explained by the mechanical stimuli exerted by muscles. 
Muscles and bones share common genetic factors and are believed to be under the influence of 
pleiotropic genes responsible for the synchronized deterioration of both tissues with age [270].  
Muscles and bones also act as endocrine target organs, which are under the influence of similar 
hormones such as testosterone and estrogen. Estradiol regulates bone resorption, and may also 
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enhance muscle contractile forces on bone [225] [226]. Androgens affect muscle mass and 
strength and trabecular bone formation [227].   
Unlike our findings among men, the risk of non-spine fractures in women with low BMD 
alone and women with both low BMD and sarcopenia was similar suggesting that low BMD may 
be the driving force for non-spine fractures in women. Although the proportion of fractures due 
to a lower degree of trauma was higher in women with low BMD and sarcopenia, statistical 
significance was not met. Gender differences in fracture risk could be explained by the fact that 
muscle strength decline is generally two times greater in men compared to women [124]. In 
addition, low testosterone levels have been associated with a decrease in muscle mass and 
strength [271]. Since men lose more testosterone with age compared to women, this decline 
could play a role in the onset and severity of sarcopenia in older men [272].  Another possible 
explanation is the inadequate power to detect the risk of non-spine fractures in sarcopenic 
women due to their small sample size.  
One of the strengths of this study is that the data were obtained from two very well 
established cohorts: MrOS and SOF, designed to understand the risk of fractures in older 
subjects. Another strength is that we adopted a unique approach in assessing the risk of non-
spine fractures by classifying participants based on their bone and body composition. 
Additionally, the use of the residuals method to assess appendicular lean mass has been shown to 
be a good predictor of mobility limitations. Other appendicular lean mass assessment methods, 
such as the appendicular skeletal muscle index, do not account for total body fat [147] [146].   
One main limitation of this study is that the definitions and algorithms of sarcopenia are 
still controversial [126]. For instance, the “International working group on sarcopenia” includes 
only the gait speed and the ratio of appendicular lean mass over height squared (ALM/height2) in 
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its algorithm without assessing muscle strength [127]. On the other hand, the Foundation for the 
National Institutes of Health (FNIH) uses the ratio of appendicular lean mass over body mass 
index for muscle mass assessment as well as different muscle strength cutoffs (with or without 
physical performance assessment).  The same analysis was repeated for the EWSOP (using 
ALM/ height2 instead of the residuals method), the international working group, and the FNIH 
operational definitions.  Although not shown here, the results were roughly the same for older 
men across all three definitions. In women, results were similar except for the FNIH definition 
which showed that participants with both low BMD and sarcopenia were not at a higher risk for 
non-spine fractures.  
To conclude, men with both low BMD and sarcopenia had a much higher risk of fractures 
compared to men with only one or neither condition. This finding was not apparent in women 
suggesting gender differences in the role of sarcopenia on osteoporotic fractures. If our results 
are confirmed, assessment of sarcopenia status concomitantly with low bone mass status may 
assist in identifying men at the highest risk of future fracture. Development of treatments for 
sarcopenia management could potentially prevent fractures, especially in older men with both 
low BMD and sarcopenia. 
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5.6 TABLES AND FIGURES 
Table 5.6.1.Baseline characteristics of older men by bone and body composition* 
 
A) In Men 
 
 
 
 
 
Characteristics Normal BMD 
and no 
sarcopenia 
(N=3367) 
Sarcopenia 
alone 
 
(N=79) 
Low BMD 
alone 
 
(N= 1986) 
Low BMD 
and 
Sarcopenia 
(N=112) 
P value 
Race 
White, n(%) 
 
3173(94) 
 
76(96) 
 
1943(98) 
 
111(99) 
 
ac 
Age (yr), mean ± SD 72.8±5.5 80.5±6.0 74.6±6.0 79.6±6.3 abcde 
Body mass index (kg/m2),  mean ± SD 28.3±3.8 26.4±3.5 26.2±3.4 24.5±2.7 abcef 
Appendicular skeletal Mass (kg),  mean ± SD 25.3±3.4 20.3±2.3 23.4±3.0 19.4±2.0 abcde 
Current smoker, n (%) 114 (3.4) 1(1.3) 68(3.4) 8(7.1)  
Alcohol use (drinks/week),  mean ± SD 4.7±7.3 5.7±10.9 3.8±5.8 3.0±5.0 acdf 
Previous fracture, n(%) 1764(52.4) 43(54.4) 1228(61.9) 64(57.1) a 
Rheumatoid arthritis, n(%) 174(5.2) 9(11.4) 89(4.5) 9(8.0) bd 
Current oral and/or inhaled steroid user, n(%) 235(7.3) 12(16.9) 196(10.2) 267(24.8) abce 
Walks for exercise, n(%) 1660(49.3) 32(40.5) 1033(52.0) 52(46.4) d 
Excellent/Good Health Status, n(%) 2917(86.7) 61(77.2) 1718(86.6) 77(68.8) bcde 
Gait speed (m/s),  mean ± SD 1.2±0.2 0.9±0.2 1.2±0.2 0.9±0.3 bcde 
Grip strength (kg),  mean ± SD 39.8.1±7.9 26.3±5.8 37.9±7.5 25.4±7.0 abcde 
Functional status 
# of IADL impairments,  mean ± SD 
 
0.3±0.8 
 
1.2±1.4 
 
0.3±0.8 
 
1.3±1.6 
 
bcde 
Any falls last 12 months, n(%) 693 (20.6) 37(46.8) 420(21.2) 32(28.6) bcdf 
2 or more falls last 12 months, n(%) 306(9.1) 21(26.6) 165(8.3) 18(16.1) bcde 
Total Hip BMD (g/cm2),  mean ± SD 
Femoral neck BMD (g/cm2),  mean ± SD 
1.03±0.11 
0.86±0.10 
0.97±0.09 
0.82±0.07 
0.84±0.09 
0.66±0.06 
0.79±0.10 
0.64±0.06 
abcdef 
abcdef 
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B) In Women 
 
Significance (p<0.05): a normal vs low BMD, b normal vs sarcopenic, c normal vs low BMD 
and sarcopenia, d low BMD vs sarcopenic, e low BMD vs low BMD and sarcopenia, f 
sarcopenia vs low BMD and sarcopenia. BMD: bone mineral density; SD: standard deviation; 
IADL: instrumental activity of daily living.  
 
 
 
 
 
 
 
 
 
 
Characteristics Normal BMD 
and no 
sarcopenia 
(N=308) 
Sarcopenia 
alone 
 
(N=48) 
Low BMD 
alone 
 
(N=626) 
Low BMD 
and 
sarcopenia 
(N= 132) 
P value 
Race 
White, n (%) 
 
65(21.1) 
 
27(56.3) 
 
393(62.8) 
 
103(78.0) 
 
bcef 
Age (yr), mean ± SD 75.6±4.2 77.0±3.5 78.3±4.3 79.1±4.0 bcdf 
Body mass index (kg/m2),  mean ± SD 30.8±4.7 28.4±4.5 26.9±4.5 27.3±4.7 bcd 
Appendicular skeletal Mass (kg),  mean ± SD 17.0±2.7 13.3±1.9 15.0±2.3 12.6±1.5 bcde 
Current smoker, n (%) 21(6.8) 4(8.3) 40(6.4) 11(8.3)  
Alcohol use (drinks/week),  mean ± SD 0.7±1.8 1.5±3.6 1.1±2.8 1.0±2.9 ab 
Previous fracture, n (%) 69(22.5) 9(18.8) 136(21.8) 24(18.2)  
Rheumatoid arthritis, n (%) 33(10.8) 5(10.4) 59(9.4) 6(4.6) c 
Current oral and/or inhaled steroid user, n (%) 15(4.9) 5(10.4) 28(4.5) 13(9.9) ce 
Walks for exercise, n (%) 119(38.8) 15(31.3) 272(43.7) 51(38.6) d 
Excellent/Good Health Status, n (%) 238(77.3) 37(77.1) 493(78.8) 104(78.8)  
Gait speed (m/s),  mean ± SD 0.86±0.21 0.86±0.19 0.90±0.22 0.88±0.20 a 
Grip strength (kg),  mean ± SD 19.7±4.9 15.5±3.8 18.5±4.8 15.6±3.5 abcde 
Functional status 
# of IADL impairments,  mean ± SD 
 
1.1±1.3 
 
1.0±1.2 
 
0.8±1.3 
 
0.8±1.1 
 
a 
Any falls last 12 months, n (%) 91(29.6) 12(25.0) 189(30.2) 44(33.3)  
2 or more falls last 12 months, n (%) 31(10.1) 5(10.4) 79(12.6) 13(9.9)  
Total Hip BMD (g/cm2),  mean ± SD 
Femoral neck BMD (g/cm2),  mean ± SD 
0.93±0.3 
0.85±0.11 
0.91±0.12 
0.83±0.09 
0.70±0.11 
0.60±0.08 
0.71±0.09 
0.61±0.08 
acdf 
acdf 
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Table 5.6.2. Hazard ratio (95% confidence intervals) for non-spine fractures by sarcopenia, 
osteopenia/osteoporosis, and sarco-osteopenia/sarco-osteoporosis* 
 
A) All fractures 
Variable (unit) Age 
adjusted 
HR 
(95% CI)  
MV adjusted  
HR(95% CI) 
Men 
Normal BMD and lean mass 1.00 (Ref) 1.00 
Sarcopenia alone 1.19(0.65,2.17) 1.14(0.62,2.09)  
Low BMD alone 1.79(1.56,2.05) 1.67(1.45,1.93) 
Low BMD and sarcopenia 3.75(2.64,5.32) 3.79(2.65,5.41) 
Women 
Normal BMD and lean mass 1.00 (Ref) 1.00 
Sarcopenia alone 1.50(0.66,3.42) 1.26(0.55,2.90) 
Low BMD alone 3.09(2.08,4.59) 2.62(1.74,3.95) 
Low BMD and sarcopenia 2.80(1.72,4.58) 2.27(1.37,3.76) 
 
 
 
 
 
87 
    B) Traumatic fractures excluded (N=167, 19% in men; N=23, 8% in women) 
Variable (unit) Age adjusted 
HR (95% CI)  
MV adjusted  
HR(95% CI) 
Men 
Normal BMD and lean mass 1.00 (Ref) 1.00 
Sarcopenia alone 1.26(0.67,2.38) 1.20(0.64,2.28)  
Low BMD alone 1.88(1.61,2.20) 1.82(1.55,2.13) 
Low BMD and sarcopenia 4.16(2.87,6.01) 4.08(2.79,5.96) 
Women 
Normal BMD and lean mass 1.00 (Ref) 1.00 
Sarcopenia alone 1.55(0.68, 3.55) 1.27(0.55,2.92) 
Low BMD alone 2.95(1.97,4.42) 2.42(1.59,3.68) 
Low BMD and sarcopenia 2.74(1.66,4.52) 2.14(1.27,3.58) 
 
*MV model:  adjustment included age, race, fall history, previous fracture, current smoking, 
steroids, rheumatoid arthritis, alcohol consumption, IADL impairments, and physical activity. 
BMD: bone mineral density; HR: hazard ratio; CI: confidence interval; IADL: instrumental 
activity of daily living 
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Figure 5.6.1. Age-adjusted incidence rate (per 1,000) of non-spine fractures by BMD 
and body composition 
 
 
 
 
 
13.2
15.1
23.4
46.5
13.9
20.7
43.0
39.0
0
5
10
15
20
25
30
35
40
45
50
Normal BMD and no
sarcopenia
Sarcopenia alone Low BMD alone Low BMD and
Sarcopenia
Ag
e-
ad
ju
st
ed
 in
ci
de
nc
e 
ra
te
 (p
er
 1
,0
00
) o
f n
on
-s
pi
ne
 fr
ac
tu
re
s
Men
Women
89 
64%
36%
Fall <standing height
Other
75%
25%
56%
44%
A) In Men 
57%
43%
Normal
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sarcopenia alone 
Low BMD alone Low BMD + sarcopenia 
 
90 
67%
33%
Fall <standing height
Other
82%
18%
75%
25%
B) In Women 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6.2. Proportion of fractures that were due to a fall from a standing height 
or less by low BMD and sarcopenia in older individuals 
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6.0  DISCUSSION 
6.1 SUMMARY, CONCLUSIONS AND FUTURE RESEARCH 
The primary aim of these three papers was to investigate the role of sarcopenia, osteoporosis, and 
osteoporotic fracture risk, and explore the muscle bone interaction. First, we were interested in 
comparing the importance of areal and volumetric BMD in fracture risk prediction.  Areal BMD 
is the gold standard for clinical assessment of fracture risk but it is a two dimensional estimate of 
integrated cortical and trabecular BMD. We tested the hypothesis that a direct measure of 
trabecular and cortical volumetric BMD (vBMD) would improve fracture prediction. We found 
that low aBMD and vBMD are both associated with multiple sites of fracture risk, and that 
trabecular vBMD had stronger associations than cortical vBMD. Nonetheless, low vBMD was 
not found to be a better predictor of major osteoporotic fractures (hip, spine, wrist, and shoulder) 
compared to aBMD, except for spine fractures. Therefore, based on these results, DXA remains 
the diagnostic imaging technique of choice to assess fracture risk in older men. Future studies 
might be needed to understand further the advantage of QCT over DXA in predicting spine 
fractures. 
Subsequently, in our second paper, we found that low appendicular lean mass (ALM) 
was associated with poorer measure of skeletal size, density, and strength as well as low spine 
and femoral neck aBMD. Although ALM was associated with all QCT parameters, grip strength 
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was related only to radius parameters. No relationship was found between leg power and QCT 
parameters. We postulated that the stronger relationship observed for ALM suggests that the 
overall mechanical load of lean mass on bones may contribute more to the skeletal size, density 
and strength than site specific measures of muscle strength and power.  Future efforts to improve 
ALM may play a key role in improving density and quality of bones, and preventing fractures. 
Longitudinal studies are needed to further establish which changes in ALM and strength 
improves skeletal size, density, and strength. Taken together, these findings highlight that ALM 
was associated with strength and geometric bone parameters that have been previously related to 
fractures. The association between grip strength was limited to a site specific effect at the radius. 
Finally, we were interested in examining whether sarcopenia with or without osteoporosis 
is associated with an increased risk of non-spine fractures. In this third paper, we demonstrated 
that men with both sarcopenia and low BMD are at a much higher risk for non-spine fractures 
compared to men with either one or neither condition. On the other hand, low BMD with or 
without sarcoepnia in women was associated with an increased risk of fractures, suggesting that 
low BMD is the driving force of non-spine fractures in older women. 
The findings of these papers shed light on the cross talk between muscle and bones. In 
fact, the loss of muscle and bone mass has been previously shown to be coupled and part of the 
same functional unit [182]. One explanation to the observed higher risk of fractures in older men 
with sarcopenia and osteoporosis combined, may be that the low ALM and grip strength in these 
men contributed to lower skeletal size, density and strength.  Therefore, assessing these muscle 
measurements concomitantly with bone strength may improve fracture risk assessment in older 
adults.  Based on this concept, identifying and exploring the risk factors related to both muscle 
and bone deterioration instead of each one alone may lead to better assessments of fractures. 
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Pleiotropy, mechanotransduction, and endocrine roles are the main etiologies responsible for the 
coordinated and progressive deterioration of the musculoskeletal system throughout life [3]. This 
is an emerging field of research and many attempts are being made to understand the etiologies 
shared by both tissues so that preventive measures and interventions could be targeted to both 
simultaneously. Therefore, future studies should investigate further the role and importance of 
pleiotropy in the synchronized deterioration of both muscles and bones. In addition, more work 
is needed to understand the role that muscles and bones play as endocrine organs. Although, it is 
clear that muscles affect both the density [3][4][5][6][7] and quality of bones [8][9], the effect of 
the bones on muscles is less well understood and should be explored. Also, identifying and 
testing for muscle/bone loss biomarkers may help detect subclinical diseases which is essential 
for primordial prevention.    
The World Health Organization (WHO) definition of osteoporosis relies on a femoral 
neck T-score of less than or equal to – 2.5 for osteoporosis diagnosis [10]. Despite the fact that 
this method is being widely used, only 20% of patients with osteoporosis experience fractures.  
In one of the papers, we compared the volumetric BMD with areal BMD without incorporating 
other bone structure and geometry parameters. We showed that vBMD was not better than 
aBMD but, future efforts should be made to incorporate other QCT bone parameters of size and 
strength with the ultimate goal of identifying individuals at a higher risk for fractures.  
Furthermore, there is no clear consensus on the definition and diagnosis of sarcopenia. 
There are currently several operational definitions. The European working group, the 
international working group, and the FNIH have developed different algorithms to identify 
individuals with sarcopenia. These algorithms differ by whether or not to include physical 
function, as well as on different gait speed and muscle strength cutoffs [11]. Furthermore, several 
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methods exist to assess low muscle mass such as the appendicular skeletal muscle mass index 
(ALM/height2), the appendicular lean mass to BMI ratio (ALM/BMI), and the residuals method 
(linear regression of appendicular lean mass by height and total body fat) [12]. Future efforts 
should be made to have consensus on one operational definition, so that diagnostic and 
therapeutic tools can be developed. 
6.2 PUBLIC HEALTH IMPLICATIONS 
The percentage of individuals older than 65 years of age is increasing. In 2008, approximately 
506 million individuals worldwide were older than 65. This number is expected to double and 
reach 14% of the world’s population by year 2040 [1]. With this increase in the older population, 
a higher number of older men and women are expected to experience deterioration in their bones 
and muscles leading to osteoporosis and sarcopenia respectively.  
Furthermore, musculoskeletal disorders are a major cause of disabilities worldwide and 
represent a major economical burden. The cost spent on musculoskeletal disorders is greater than 
the cost of breast cancer, stroke, and cardiovascular diseases combined [3]. Therefore, it is of 
primary importance to understand the burden that osteoporosis and sarcopenia represent in older 
men and women. Doing so would help in preventing future fractures and thus, poor health 
outcomes. In fact, mortality and morbidity are two major consequences of osteoporosis, 
primarily due to hip fractures [65]. Worldwide, the total Disability Adjusted Life Years 
(DALYs) lost attributed to fractures was about 58 million [228]. In Medicare enrollees, while hip 
fractures had the highest excess cost, multiple types of fractures were also associated with higher 
health care expenditures [229] [65]. 
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The work included in this dissertation has important public health implications. Despite 
advances in technology, there was no evidence that trabecular vBMD was superior to aBMD. 
Therefore, DXA remains the gold standard for bone fracture assessment. Its’ low cost, quickness, 
low radiation and precision makes the DXA a good screening tool that should be utilized more 
frequently to prevent fractures in community dwelling adults. Furthermore, diagnosing and 
preventing sarcopenia may also be important in preventing falls.  
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